EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	21	"469361"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/10/25 16:43
L2	18	"495405"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/10/25 16:43
L3	7	(US-20040110794-$ or US-20040110952-$ or US-20040006081-$ or US-20050014788-$).did. or (US-6288084-$).did. or (EP-1013276-$).did. or (EP-1013276-$).did.	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2007/10/25 16:44
L4	896	514/316.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/10/25 16:45
L5	75	L4 and chemokine	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/10/25 16:45
S1	19	"014322"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/10/23 17:20
S2	0	"514""."326".ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/10/23 17:20

EAST Search History

S4	181	S3 and chemokine	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/10/23 17:58
S5	17	"429605"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/10/24 15:16
S6	6	"4353734"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/10/24 15:24
S7	16	"535795"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/10/24 15:34
S8	35	"284220"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/10/24 15:34
S9	14	"841672"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/10/24 15:35
S10	24	"966646"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/10/25 12:41

EAST Search History

S11	896	514/316.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/10/25 13:13
S12	17	EP1013276	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/10/25 13:14
S13	39	"1013276"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/10/25 13:17
S14	841	armour.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/10/25 13:20
S15	11	S14 and ccr5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/10/25 13:20

```
Connecting via Winsock to STN

Welcome to STN International:  Enter x:X

LOGINID:SSPTADK01625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1              Web Page for STN Seminar Schedule - N. America
 NEWS  2  JUL 02      LMEDLINE coverage updated
 NEWS  3  JUL 02      SCISEARCH enhanced with complete author names
 NEWS  4  JUL 02      CHEMCATS accession numbers revised
 NEWS  5  JUL 02      CA/CAplus enhanced with utility model patents from China
 NEWS  6  JUL 16      CAplus enhanced with French and German abstracts
 NEWS  7  JUL 18      CA/CAplus patent coverage enhanced
 NEWS  8  JUL 26      USPATFULL/USPAT2 enhanced with IPC reclassification
 NEWS  9  JUL 30      USGENE now available on STN
 NEWS 10  AUG 06      CAS REGISTRY enhanced with new experimental property tags
 NEWS 11  AUG 06      FSTA enhanced with new thesaurus edition
 NEWS 12  AUG 13      CA/CAplus enhanced with additional kind codes for granted
                      patents
 NEWS 13  AUG 20      CA/CAplus enhanced with CAS indexing in pre-1907 records
 NEWS 14  AUG 27      Full-text patent databases enhanced with predefined
                      patent family display formats from INPADOCDB
 NEWS 15  AUG 27      USPATOLD now available on STN
 NEWS 16  AUG 28      CAS REGISTRY enhanced with additional experimental
                      spectral property data
 NEWS 17  SEP 07      STN AnaVist, Version 2.0, now available with Derwent
                      World Patents Index
 NEWS 18  SEP 13      FORIS renamed to SOFIS
 NEWS 19  SEP 13      INPADOCDB enhanced with monthly SDI frequency
 NEWS 20  SEP 17      CA/CAplus enhanced with printed CA page images from
                      1967-1998
 NEWS 21  SEP 17      CAplus coverage extended to include traditional medicine
                      patents
 NEWS 22  SEP 24      EMBASE, EMBAL, and LEMBASE reloaded with enhancements
 NEWS 23  OCT 02      CA/CAplus enhanced with pre-1907 records from Chemisches
                      Zentralblatt
 NEWS 24  OCT 19      BEILSTEIN updated with new compounds

 NEWS EXPRESS   19 SEPTEMBER 2007:  CURRENT WINDOWS VERSION IS V8.2,
                CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
                AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

 NEWS HOURS     STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN     Welcome Banner and News Items
 NEWS IPC8      For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.
```



```
* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:12:53 ON 25 OCT 2007

=> file caplus
FILE 'CAPLUS' ENTERED AT 11:13:06 ON 25 OCT 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
```



```
FILE COVERS 1907 - 25 Oct 2007  VOL 147 ISS 18
FILE LAST UPDATED: 24 Oct 2007  (20071024/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> e shehata/au
E1             1      SHEHASTNYI P N/AU
E2             1      SHEHAT A H/AU
E3             0 --> SHEHATA/AU
E4             8      SHEHATA A/AU
E5            14      SHEHATA A A/AU
E6             7      SHEHATA A A Y/AU
E7             1      SHEHATA A ADEL/AU
E8            19      SHEHATA A ADEL Y/AU
E9            23      SHEHATA A B/AU
E10           28      SHEHATA A E/AU
E11            3      SHEHATA A EL TABEY/AU
E12            2      SHEHATA A F/AU

=> s E4-E8
               8 "SHEHATA A"/AU
              14 "SHEHATA A A"/AU
               7 "SHEHATA A A Y"/AU
               1 "SHEHATA A ADEL"/AU
              19 "SHEHATA A ADEL Y"/AU
L1            49 ("SHEHATA A"/AU OR "SHEHATA A A"/AU OR "SHEHATA A A Y"/AU OR
                 "SHEHATA A ADEL"/AU OR "SHEHATA A ADEL Y"/AU)

=> analyze
ENTER ANSWER SET OR ANALYZE L# OR (L1):l1
ENTER ANSWER NUMBER OR RANGE (1-):49
ENTER DISPLAY CODE (TI) OR ?:jn
'JN' IS NOT A VALID FIELD CODE FOR FILE 'CAPLUS'
The following are valid field codes:
AB ------ Abstract Text
AC ------ Patent Application Country
AD ------ Patent Application Date
AI ------ Patent Application Information
AN ------ Accession Number
AP ------ Patent Application Number
APPS ---- Patent Application and Priority Number
AU ------ Author or Patent Inventor
AY ------ Patent Application Year
CC ------ CA Classification Codes
CS ------ Corporate Source or Patent Assignee
CS.DIV -- Corporate Source, Division
CS.ORG -- Corporate Source, Organization Name
CT ------ Controlled Term
CYA ----- Country Name of Author
DS ------ Designated States (Patents)
DT ------ Document Type
FAN ----- Family Accession Number
FS ------ File Segment
GENBANK - GENBANK Number
IC ------ International Patent Classification (IPC)
ICA ----- Additional (Supplementary) IPC
ICI ----- Index (Complementary) IPC
ICM ----- Main IPC
ICS ----- Secondary IPC
IN ------ Inventor Name
ISN ----- International Standard (Document) Number
ISSN----- ISSN
IPC ----- International Patent Classifications
IT ------ Index Entries
JT ------ Journal Title
LA ------ Language
NCL------ National Patent Classification Code
OS ------ Other Source
PA ------ Patent Assignee
PATS----- Patent Numbers
PC ------ Patent Country
PCS ----- Patent Countries
PD ------ Publication Date
PI ------ Patent Information
PK ------ Kind of Patent
PN ------ Patent Number
PRAI ---- Patent Priority Information
PRC ----- Patent Priority Country
PRD ----- Patent Priority Date
PRN ----- Patent Priority Number
PRY ----- Patent Priority Year
PY ------ Publication Year of Original Document
RE ------ Reference
REC ----- Reference Count
RAN.CA -- Reference CA File Accession Number
RAN.CAPLUS --- Reference CAPlus File Accession Number
RAN.MEDLINE -- Reference MEDLINE File Accession Number
RAN.ALL ------ Reference Accession Numbers for All Files
RIN ----- Reference Inventor
RAU ----- Reference Author
RWK ----- Reference Work
RPG ----- Reference Page Number
RPN ----- Reference Patent Number
RPY ----- Reference Publication Year
RVL ----- Reference Publication Volume
RL ------ Roles
RN ------ CAS Registry Number
SO ------ Source
ST ------ Supplementary Terms (CA Keywords)
SX ------ Chemical Abstract Section Cross-Reference Code
TI ------ Title of Document
ENTER DISPLAY CODE (TI) OR ?:jt
L2            ANALYZE L1 49 JT :        2 TERMS

=> d l2
L2            ANALYZE L1 49 JT :        2 TERMS

TERM #   # OCC  # DOC  % DOC JT
------ ------- ------ ------ --------------
     1       1      1 100.00 CAN. INST. FOOD TECHNOL., J.
     2       1      1 100.00 CANADIAN INSTITUTE OF FOOD TECHNOLOGY JOURNAL
*********  END OF L2 ***


=> e zahran/au
E1            20      ZAHRAMAN K/AU
E2             5      ZAHRAMAN KHALED/AU
E3             0 --> ZAHRAN/AU
E4             9      ZAHRAN A A/AU
E5            55      ZAHRAN A H/AU
E6             1      ZAHRAN A M/AU
E7             1      ZAHRAN A M I/AU
E8             1      ZAHRAN A R R/AU
E9            14      ZAHRAN A S/AU
E10            1      ZAHRAN ABDEL RAHMAN/AU
E11            1      ZAHRAN ABUL Y/AU
E12            2      ZAHRAN AFAF A/AU

=> e zahran m/au
E1             1      ZAHRAN J/AU
E2             1      ZAHRAN JAY/AU
E3             7 --> ZAHRAN M/AU
E4            47      ZAHRAN M A/AU
E5             3      ZAHRAN M G/AU
E6            23      ZAHRAN M K/AU
E7             3      ZAHRAN M M/AU
E8             2      ZAHRAN MAGDI/AU
E9             3      ZAHRAN MAGDY/AU
E10           11      ZAHRAN MAGDY A/AU
E11            1      ZAHRAN MAGDY A H/AU
E12            1      ZAHRAN MAGDY K/AU

=> e zahran m? a?/au
E1            23      ZAHRAN M K/AU
E2             3      ZAHRAN M M/AU
E3             0 --> ZAHRAN M? A?/AU
E4             2      ZAHRAN MAGDI/AU
E5             3      ZAHRAN MAGDY/AU
E6            11      ZAHRAN MAGDY A/AU
E7             1      ZAHRAN MAGDY A H/AU
E8             1      ZAHRAN MAGDY K/AU
E9             3      ZAHRAN MAGDY KANDIL/AU
E10            5      ZAHRAN MAHMOUD/AU
E11            1      ZAHRAN MAHMOUD A/AU
E12            1      ZAHRAN MAI/AU
```


```
=> e zahran m/au
E1             1      ZAHRAN J/AU
E2             1      ZAHRAN JAY/AU
E3             7 --> ZAHRAN M/AU
E4            47      ZAHRAN M A/AU
E5             3      ZAHRAN M G/AU
E6            23      ZAHRAN M K/AU
E7             3      ZAHRAN M M/AU
E8             2      ZAHRAN MAGDI/AU
E9             3      ZAHRAN MAGDY/AU
E10           11      ZAHRAN MAGDY A/AU
E11            1      ZAHRAN MAGDY A H/AU
E12            1      ZAHRAN MAGDY K/AU
```


```
=> s e4
L3            47 "ZAHRAN M A"/AU

=> d his

     (FILE 'HOME' ENTERED AT 11:12:53 ON 25 OCT 2007)

     FILE 'CAPLUS' ENTERED AT 11:13:06 ON 25 OCT 2007
                E SHEHATA/AU
L1            49 S E4-E8
L2            ANALYZE L1 49 JT :        2 TERMS
                E ZAHRAN/AU
                E ZAHRAN M/AU
                E ZAHRAN M? A?/AU
                E ZAHRAN M/AU
L3            47 S E4

=> s l1 and l3
L4             2 L1 AND L3

=> d cbib abs 1-2

L4   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2007 ACS on STN
1995:460770   Document No. 123:55738  Synthesis of some new visnagin
     derivatives.  Ali, M. M.; Mohamed, Y. A.; Zahran, M. A.;
     Shehata, A. A. (Faculty Science, Al-Azhar University, Cairo,
     Egypt).  Ultra Scientist of Physical Sciences, 6(2), 164-9 (English) 1994.
     CODEN: USPSE5.
GI
```



```
AB   Condensation of visnagin (I, R = H, X = O) or visnagin-9-sulfonamides (I; R =
     SO2NMe2, SO2NEt2; X = O) with nucleophilic reagents, such as thiourea,
     guanidine, hydrazine, hydroxylamine and potassium hydroxide, gave products of
     fission of the γ-pyrone ring.  Thionation of I (R = SO2NMe2, SO2NEt2; X = O)
     with phosphorus pentasulfide gave I (R = SO2NMe2, SO2NEt2; X = S).
     Condensation of benzopyranone II with active methylene compds. such as di-Et
     malonate, Et cyanoacetate, malonic acid, Et acetoacetate, phenylacetic acid,
     acetylglycine, and benzoylglycine caused ring closure and the γ-pyrano derivs.
     were obtained.


L4   ANSWER 2 OF 2  CAPLUS  COPYRIGHT 2007 ACS on STN
1994:482766   Document No. 121:82766  A facile synthesis of pyranochromone and
     pyranocoumarin derivatives.  Zahran, M. A.; Ali, M. M.; Mohamed,
     Y. A.; Shehata, A. A  (Fac. Sci., Al-Azhar Univ., Nasr, Egypt).
     International Journal of Chemistry, 4(3), 61-8 (English) 1993.  CODEN:
     IMJCEW.
GI
```



```
AB   The benzopyranones I and II, derived from visnagin and bergapten, resp.,
     reacted with active methylene compds. to give variously substituted
     benzodipyranones.  Schiff bases of II were also prepared



=> e onischu/au
E1             2      ONISCHENKO YURI/AU
E2             7      ONISCHOUK V A/AU
E3             0 --> ONISCHU/AU
E4             1      ONISCHUK A/AU
E5            24      ONISCHUK A A/AU
E6             2      ONISCHUK ANDREI A/AU
E7             3      ONISCHUK L A/AU
E8             1      ONISCHUK LOREEN ANN/AU
E9             1      ONISCHUK S F/AU
E10            1      ONISCHUK V/AU
E11            8      ONISCHUK V A/AU
E12            1      ONISCHUK Y N/AU

=> e oniscu/au
E1             1      ONISCHUK Y N/AU
E2             1      ONISCIU CORNELIU/AU
E3             0 --> ONISCU/AU
E4             1      ONISCU A/AU
E5             1      ONISCU ANCA/AU
E6            66      ONISCU C/AU
```

```
E7            1     ONISCU CORNEL/AU
E8            2     ONISCU CORNELIA/AU
E9          131     ONISCU CORNELIU/AU
E10           1     ONISCU G/AU
E11           1     ONISCU G C/AU
E12           2     ONISCU GABRIEL CORNELIU/AU

=> s e6-e9
            66 "ONISCU C"/AU
             1 "ONISCU CORNEL"/AU
             2 "ONISCU CORNELIA"/AU
           121 "ONISCU CORNELIU"/AU
L5         190 ("ONISCU C"/AU OR "ONISCU CORNEL"/AU OR "ONISCU CORNELIA"/AU OR
               "ONISCU CORNELIU"/AU)

=> e nicoara/au
E1            2     NICO VAN DER RIET/AU
E2            1     NICOALE M/AU
E3            1 --> NICOARA/AU
E4           10     NICOARA A/AU
E5           30     NICOARA ADRIAN/AU
E6            3     NICOARA ADRIANA E/AU
E7            1     NICOARA ADRIANA GABRIELA/AU
E8            1     NICOARA AL/AU
E9            1     NICOARA ALEXANDRA/AU
E10           3     NICOARA ALEXANDRU/AU
E11           5     NICOARA AMA/AU
E12           1     NICOARA B/AU

=> e nicoara d/au
E1            1     NICOARA CORINA/AU
E2            1     NICOARA CRISTIANA/AU
E3           18 --> NICOARA D/AU
E4            2     NICOARA DELIA/AU
E5            5     NICOARA DOINA MARIETA/AU
E6            4     NICOARA DORU/AU
E7           26     NICOARA DUMITRU/AU
E8            2     NICOARA DUMITRU RO/AU
E9           15     NICOARA E/AU
E10          30     NICOARA ELENA/AU
E11           2     NICOARA EUFEMIA AMA/AU
E12           5     NICOARA EUFEMIA RO/AU

=> s e3-e8
            18 "NICOARA D"/AU
             2 "NICOARA DELIA"/AU
             5 "NICOARA DOINA MARIETA"/AU
             4 "NICOARA DORU"/AU
            26 "NICOARA DUMITRU"/AU
             2 "NICOARA DUMITRU RO"/AU
L6          57 ("NICOARA D"/AU OR "NICOARA DELIA"/AU OR "NICOARA DOINA MARIETA"
               /AU OR "NICOARA DORU"/AU OR "NICOARA DUMITRU"/AU OR "NICOARA
              DUMITRU RO"/AU)

=> d his

     (FILE 'HOME' ENTERED AT 11:12:53 ON 25 OCT 2007)

     FILE 'CAPLUS' ENTERED AT 11:13:06 ON 25 OCT 2007
                E SHIMATA/AU

L1           49 S E4-E8
L2          ANALYZE L1 49 JT :       2 TERMS
                E ZAMRAN/AU
                E ZAMRAN M/AU
                E ZAMRAN M? A?/AU
                E ZAMRAN N/AU
L3          47 S E4
L4           2 S L1 AND L3
                E ONISCHU/AU
                E ONISCU/AU
L5         190 S E4-E9
                E NICOARA/AU
                E NICOARA D/AU
L6          57 S E3-E9

=> s 15 and 16
L7           1 L5 AND L6

=> d cbib abs

L7   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2007 ACS on STN
1983:539533  Document No. 99:139533  4-(Dreidosulfonyl)phenylacetic acid and
its ureide.. Oniscu, Cornelia; Niccara, Doru;
Puniaru, Gabriela (Institutul de Cercetari Chimico-Farmaceutice, Rom.).
Rom. RO 75930 A2 19810228, 3 pp.  (Romanian).  CODEN: RUXXA3.
APPLICATION: RO 1979-84646 19790219.
GI

                    H2NCONHSO2-C6H4-CH2COR
                                      I

AB   Phenylacetic acid derivs. I (R = OH, NHCONH2), useful as anticonvulsants and
antidiabetics (no data), were prepared  Thus, 4-(H2NSO2)C6H4CH2CO2H reacted
with KOCN to yield I (R = OH), and the latter was heated with urea in Ac2O to
give I (R = NHCONH2).


=> FIL STNGUIDE
FILE 'STNGUIDE' ENTERED AT 11:28:10 ON 25 OCT 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Oct 19, 2007 (20071019/UP).

=> fils casreact
FILE 'CASREACT' ENTERED AT 11:29:25 ON 25 OCT 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.

FILE CONTENT:1840 - 20 Oct 2007 VOL 147 ISS 16

New CAS Information Use Policies, enter HELP USAGETERMS for details.

**********************************************************
*                                                        *
*     CASREACT now has more than 13.0 million reactions  *
*                                                        *
**********************************************************

Some CASREACT records are derived from the EIC/VINITI database (1974-1999)
provided by InfoChem, IMPI data prior to 1986, and Biotransformations
database compiled under the direction of Professor Dr. Klaus Kieslich.

This file contains CAS Registry Numbers for easy and accurate substance
identification.

=> d his

     (FILE 'HOME' ENTERED AT 11:12:53 ON 25 OCT 2007)

     FILE 'CAPLUS' ENTERED AT 11:13:06 ON 25 OCT 2007
                E SHIMATA/AU
L1           49 S E4-E8
L2          ANALYZE L1 49 JT :       2 TERMS
                E ZAMRAN/AU
                E ZAMRAN M/AU
                E ZAMRAN M? A?/AU
                E ZAMRAN N/AU
L3          47 S E4
L4           2 S L1 AND L3
                E ONISCHU/AU
                E ONISCU/AU
L5         190 S E4-E9
                E NICOARA/AU
                E NICOARA D/AU
L6          57 S E3-E9
L7           1 S L5 AND L6

     FILE 'STNGUIDE' ENTERED AT 11:28:10 ON 25 OCT 2007

     FILE 'CASREACT' ENTERED AT 11:29:25 ON 25 OCT 2007

=> s l7
             7 "ONISCU C"/AU
             0 "ONISCU CORNEL"/AU
             1 "ONISCU CORNELIA"/AU
            13 "ONISCU CORNELIU"/AU
             0 "NICOARA D"/AU
             0 "NICOARA DELIA"/AU
             2 "NICOARA DOINA MARIETA"/AU
             1 "NICOARA DORU"/AU
             0 "NICOARA DUMITRU"/AU
             0 "NICOARA DUMITRU RO"/AU
L8           1 L5 AND L6

=> s help
Enter the terms you wish to use in your search profile.

ENTER LOGIC EXPRESSION, QUERY NAME, OR (END):end
SEARCH ENDED BY USER

=> help s fields
HELP FOR 'S FIELDS' IS NOT AVAILABLE
For information about help messages available in all files, enter
"HELP MESSAGES".  For information about help messages available for
the current file, enter "HELP DIRECTORY".  For a list of commands,
enter "HELP COMMANDS".

=> help s
HELP FOR 'S ' IS NOT AVAILABLE
For information about help messages available in all files, enter
"HELP MESSAGES".  For information about help messages available for
the current file, enter "HELP DIRECTORY".  For a list of commands,
enter "HELP COMMANDS".

=> help
The arrow (=>) is the system prompt, where you enter a command.  For
an explanation of system commands, files, formats, etc., enter "HELP"
and the name of the item you want explained at an arrow prompt (=>).
Enter "HELP COMMANDS" for a list of commands that can be used in this
file.  Enter "HELP MESSAGES" for a list of online explanations that
are available.  The "?" can be used as a synonym for "HELP".

Help is also available at any prompt, and after any error message.
Enter "HELP" or "?" at a prompt to see an explanation of the options.
After an error message, enter "HELP" or "?" at the next prompt and you
will receive a more detailed explanation of the error and how to
correct it.

Automatic help is also available.  When AUHELP is 'ON', you will
automatically receive help following an error message.  For more
information on AUHELP, enter "HELP SET AUHELP" at an arrow
prompt (=>).

Users who need additional assistance can contact the Help Desk at
their nearest STN Service Center.  Enter "HELP STN" for information on
STN Service Centers.  You may also choose to contact the database
representative for the file you are searching, for more detailed help
on database content and search strategy.  For information on how to
contact database representatives for the current file, enter "HELP
DESK" at an arrow prompt (=>).

=> help commands
Enter one of these commands at the arrow prompt (=>).

ACTIVATE ----- Assign L#s to saved query or answer set.
ANALYZE ------ Build expand terms from answer fields.
ARCHIVE ------ Purchase rights for archiving.
BATCH -------- Request a batch search.
DELETE ------- Delete saved or current session items.
DISPLAY ------ Display saved or current session items.
DUPLICATE ---- Determine duplicate answers
EDIT --------- Modify the text of an E-number entry.
EXPAND ------- Look at the index around a term.
FILE --------- Specify the search and display file.
HELP --------- For help on how to use the system.
INDEX -------- Specify the Index environment.
LOGOFF ------- End the online session.

NEWS --------- Display current news about the system.
ORDER -------- Order an original document or copy.
PRINT -------- Print answers offline.
QUERY -------- Define a search question (query).
REDISTRIBUTE - Purchase rights for redistribution.
SAVE --------- Save an L-numbered query or answer set.
SCREEN ------- Define a set of screens for searching.
SDI ---------- Request searches be run on file updates.
SEARCH ------- Perform a search.
SELECT ------- Build expand terms from answer fields.
SET ---------- Set terminal and interaction options.
SORT --------- Sort Answers of an L-number list
STRUCTURE ---- Create a structure for searching.
TABULATE ----- Analyze SmartSELECT L-number data.
TRANSFER ----- Extract terms from answers and search.
? ------------ The same as HELP.
Enter one of these commands at the arrow prompt (=>).

For more detailed information about a command, enter HELP followed by
the command name at an arrow prompt.

Example: => HELP SEARCH

For information on entering multiple commands at a single arrow
prompt, enter HELP COMMAND STACKING.

=> dhis
DHIS IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> d his

     (FILE 'HOME' ENTERED AT 11:12:53 ON 25 OCT 2007)

     FILE 'CAPLUS' ENTERED AT 11:13:06 ON 25 OCT 2007
                E SHIMATA/AU
L1           49 S E4-E8
L2          ANALYZE L1 49 JT :       2 TERMS
                E ZAMRAN/AU
                E ZAMRAN M/AU
                E ZAMRAN M? A?/AU
                E ZAMRAN N/AU
L3          47 S E4
L4           2 S L1 AND L3
                E ONISCHU/AU
                E ONISCU/AU
L5         190 S E4-E9
                E NICOARA/AU
                E NICOARA D/AU
L6          57 S E3-E9
L7           1 S L5 AND L6

     FILE 'STNGUIDE' ENTERED AT 11:28:10 ON 25 OCT 2007

     FILE 'CASREACT' ENTERED AT 11:29:25 ON 25 OCT 2007
L8           1 S L7

=> d l8 fcrd

L8   ANSWER 1 OF 1  CASREACT  COPYRIGHT 2007 ACS on STN
     NO HIGHLIGHTING INFORMATION PRESENT


=> help d
HELP FOR 'D' IS NOT AVAILABLE
For information about help messages available in all files, enter
"HELP MESSAGES".  For information about help messages available for
the current file, enter "HELP DIRECTORY".  For a list of commands,
enter "HELP COMMANDS".

=> d help

The following are valid formats:

ABS ---------- GI and AB
ALL ---------- BIB, AB, IND, RE, Single-step Reactions
APPS --------- AI, PRAI
BIB ---------- AN, plus Bibliographic Data
CAN ---------- List of CA abstract numbers without answer numbers
CBIB --------- AN, plus Compressed Bibliographic Data
DALL --------- ALL, delimited (end of each field identified)
IABS --------- ABS, indented with text labels
IALL --------- ALL, indented with text labels
IBIB --------- BIB, indented with text labels
IND ---------- Indexing data
IPC ---------- International Patent Classifications
ISTD --------- STD, indented with text labels
OBIB --------- AN, plus Bibliographic Data (original)
OIBIB -------- OBIB, indented with text labels

SBIB --------- BIB, no citations
SIBIB -------- IBIB, no citations

MAX ---------- Same as ALL
PATS --------- PI, SO
SCAN --------- TI and FCRD (random display, no answer number.  SCAN
               must be entered on the same line as DISPLAY, e.g.,
               D SCAN.)
SSRX --------- Single-Step Reactions (Map, Diagram, and Summary for
               all single-step reactions)
STD ---------- BIB, IPC, and NCL

CRD ---------- Compact Display of All Hit Reactions
CRDREF ------- Compact Reaction Display and SO, PY for Reference
FHIT --------- Reaction Map, Diagram, and Summary for first
               hit reaction
FHITCBIB ----- FHIT, AN plus CBIB
FCRD --------- First hit in Compact Reaction Display (CRD) format
FCRDREF ------ First hit in Compact Reaction Display (CRD) format with
               CA reference information (SO, PY).  (Default)
FPATH -------- PATH, plus Reaction Summary for the "long path"
FSPATH ------- SPATH, plus Reaction Summary for the "short path"
HIT ---------- Reaction Map, Reaction Diagram, and Reaction
               Summary for all hit reactions and fields containing
               hit terms
OCC ---------- All hit fields and the number of occurrences of the
               hit terms in each field.  Includes total number of
```

HIT, PATH, SPATH reactions. Labels reactions that have
incomplete verifications.
PATH ------- Reaction Map and Reaction Diagram for the "long
path". Displays all hit reactions, except those
whose steps are totally included within another hit
reaction which is displayed
RX --------- Hit Reactions (Map, Diagram, Summary for all hit reactions)
RXG -------- Hit Reaction Graphics (Map and Diagram for all hit reactions)
RXL -------- Hit Reaction Long (Map, Diagram, Summary for all hit reactions)
RXS -------- Hit Reaction Summariers (Map and Summary for all hit reactions)
SPATH ------ Reaction Map and Reaction Diagram for the "short
path". Displays all single step reactions which
contain a hit substance. Also displays those
multistep reactions that have a hit substance in both
the first and last steps of the reaction, except for
those hit reactions whose steps are totally included
within another hit reaction which is displayed

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of combinations include: D TI; D BIB RX; D TI, AU, FCRD. The information is displayed in the same order as the specification. All of the formats, except CRD, CRDREF, FHIT, FATH, FPATH, SPATH, FSPATH, FCRD, FCRDREF, HIT, RX, RXG, RXS, SCAN, and OCC, may be used with the DISPLAY command to display the record for a specified Accession Number.

L8 ANSWER 1 OF 1 CASREACT COPYRIGHT 2007 ACS on STN
NO HIGHLIGHTING INFORMATION PRESENT

=> d his

(FILE 'HOME' ENTERED AT 11:12:53 ON 25 OCT 2007)

FILE 'CAPLUS' ENTERED AT 11:13:06 ON 25 OCT 2007
E SHEHATA/AU
L1 49 S E4-E8
L2 ANALYZE L1 49 JT : 2 TERMS
E ZAHRAN/AU
E ZAHRAN M/AU
E ZAHRAN M? A?/AU
E ZAHRAN M/AU
L3 47 S E4
L4 2 S L1 AND L3
E ONISCHU/AU
E ONISCU/AU
L5 190 S E6-E9
E NICOARA/AU
E NICOARA D/AU
L6 57 S E3-E8
L7 1 S L5 AND L6

FILE 'STNGUIDE' ENTERED AT 11:28:10 ON 25 OCT 2007

FILE 'CASREACT' ENTERED AT 11:29:25 ON 25 OCT 2007
L8 1 S L7

=> d all l8

L8 ANSWER 1 OF 1 CASREACT COPYRIGHT 2007 ACS on STN
AN 99:139533 CASREACT Full-text
TI 4-(Ureidosulfonyl)phenylacetic acid and its ureide.
IN Onisecu, Corneliu; Nicoara, Doru; Funieru, Gabriela
PA Institutul de Cercetari Chimico-Farmaceutice, Rom.
SO Rom., 3 pp.
CODEN: RUXXA3
DT Patent
LA Romanian
IC C07C127-19
CC 25-19 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	RO 75530	A2	19810228	RO 1979-96646	19790219
PRAI	RO 1979-96646		19790219		

GI


I

AB Phenylacetic acid derivs. I (R = OH, NHCONH2), useful as anticonvulsants and antidiabetics (no data), were prepared Thus, 4-(H2NSO3)C6H4CH2CO2H reacted with KOCN to yield I (R = OH), and the latter was heated with urea in Ac2O to give I (R = NHCONH2).
ST phenylacetamide ureidosulfonyl prepn anticonvulsant;
ureidosulfonylphenylacetic ureide prepn anticonvulsant; antidiabetic
ureidosulfonylphenylacetic ureide prepn
IT Anticonvulsants and Antiepileptics
Antidiabetics and Hypoglycemics
((ureidosulfonyl)phenylacetic acid and ureide derivative)
IT 7664-41-7, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(amidation by, of (carbethoxymethyl)benzenesulfonyl chloride)
IT 57-13-6, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(amidation by, of phenylacetic acid derivative)
IT 101-97-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(chlorosulfonylation of)
IT 87202-52-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and amidation of, by ammonia)
IT 87202-53-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and amidation of, by urea)
IT 22958-64-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and reaction of, with potassium cyanate)
IT 836-13-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and saponification of)
IT 87202-54-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RX(1) OF 10 A ===> B...





RX(1) RCT A 101-97-3
PRO B 836-13-5

RX(2) OF 10 ...B ===> C...



RX(2) RCT B 836-13-5
PRO C 22958-64-1

RX(3) OF 10 ...C ===> D...





RX(3) RCT C 22958-64-1
PRO D 87202-53-7

RX(4) OF 10 ...D + E ===> F





RX(4) RCT D 87202-53-7, E 57-13-6
PRO F 87202-54-8

=> d his

(FILE 'HOME' ENTERED AT 11:12:53 ON 25 OCT 2007)

FILE 'CAPLUS' ENTERED AT 11:13:06 ON 25 OCT 2007
E SHEHATA/AU
L1 49 S E4-E8
L2 ANALYZE L1 49 JT : 2 TERMS
E ZAHRAN/AU
E ZAHRAN M/AU
E ZAHRAN M? A?/AU
E ZAHRAN M/AU
L3 47 S E4
L4 2 S L1 AND L3
E ONISCHU/AU
E ONISCU/AU
L5 190 S E6-E9
E NICOARA/AU .
E NICOARA D/AU
L6 57 S E3-E8
L7 1 S L5 AND L6

FILE 'STNGUIDE' ENTERED AT 11:28:10 ON 25 OCT 2007

FILE 'CASREACT' ENTERED AT 11:29:25 ON 25 OCT 2007
L8 1 S L7

=> s 14
0 "SHEHATA A"/AU
2 "SHEHATA A A"/AU
0 "SHEHATA A A Y"/AU
0 "SHEHATA A ADEL"/AU
0 "SHEHATA A ADEL Y"/AU
19 "ZAHRAN M A"/AU
L9 0 L1 AND L3

=> FIL STNGUIDE
FILE 'STNGUIDE' ENTERED AT 11:37:24 ON 25 OCT 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Oct 19, 2007 (20071019/UP).

=> FIL REGISTRY

FILE 'REGISTRY' ENTERED AT 11:38:18 ON 25 OCT 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 23 OCT 2007 HIGHEST RN 951288-30-5
DICTIONARY FILE UPDATES: 23 OCT 2007 HIGHEST RN 951288-30-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> S 101-97-3/RN

L10 1 101-97-3/RN

=> SET NOTICE 1000 DISPLAY

NOTICE SET TO 1000 U.S. DOLLARS FOR DISPLAY COMMAND
SET COMMAND COMPLETED

=> D L10 SQIDE 1-

YOU HAVE REQUESTED DATA FROM 1 ANSWERS - CONTINUE? Y/(N):y

L10 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN
RN 101-97-3 REGISTRY
CN Benzeneacetic acid, ethyl ester (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Acetic acid, phenyl-, ethyl ester (6CI, 8CI)
OTHER NAMES:
CN α-Toluic acid ethyl ester
CN 2-Phenylacetic acid ethyl ester
CN Ethyl α-phenylacetate
CN Ethyl α-toluate
CN Ethyl 2-phenylacetate
CN Ethyl 2-phenylethanoate
CN Ethyl benzeneacetate
CN Ethyl phenacetate
CN Ethyl phenylacetate
CN NSC 406259
CN NSC 8894
CN Phenylacetic acid ethyl ester
MF C10 H12 O2
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CSCHEM, DETHERM*, GMELIN*, IFICDB, IFIPAT, IFIUDB, MRCK*, MSDS-OHS, NAPRALERT, PROMT, PS, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL, USPATOLD
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)
DT.CA CAplus document type: Conference; Journal; Patent; Preprint; Report
RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)
RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); USES (Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)
RLD.NP Roles for non-specific derivatives from non-patents: PREP

(Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1657 REFERENCES IN FILE CA (1907 TO DATE)
9 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1662 REFERENCES IN FILE CAPLUS (1907 TO DATE)
46 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> SET NOTICE LOGIN DISPLAY

NOTICE SET TO OFF FOR DISPLAY COMMAND
SET COMMAND COMPLETED

=>

=> FIL STNGUIDE
FILE 'STNGUIDE' ENTERED AT 11:42:21 ON 25 OCT 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Oct 19, 2007 (20071019/UP).

=>
Connecting via Winsock to STN

Welcome to STN International: Enter x:X

LOGINID:SSPTADE01625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 JUL 02 LMEDLINE coverage updated
NEWS 3 JUL 02 SCISEARCH enhanced with complete author names
NEWS 4 JUL 02 CHEMCATS accession numbers revised
NEWS 5 JUL 02 CA/Caplus enhanced with utility model patents from China
NEWS 6 JUL 16 CAplus enhanced with French and German abstracts
NEWS 7 JUL 18 CA/Caplus patent coverage enhanced
NEWS 8 JUL 24 USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 9 JUL 30 USGENE now available on STN
NEWS 10 AUG 06 CAS REGISTRY enhanced with new experimental property tags
NEWS 11 AUG 06 FSTA enhanced with new thesaurus edition
NEWS 12 AUG 13 CA/CAplus enhanced with additional kind codes for granted patents
NEWS 13 AUG 20 CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 14 AUG 27 Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 15 AUG 27 USPATOLD now available on STN
NEWS 16 AUG 28 CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 17 SEP 07 STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 18 SEP 13 PORIS renamed to SOPIS
NEWS 19 SEP 13 INPADOCDB enhanced with monthly SDI frequency
NEWS 20 SEP 17 CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS 21 SEP 17 CAplus coverage extended to include traditional medicine patents
NEWS 22 SEP 24 EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 23 OCT 02 CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 24 OCT 19 BEILSTEIN updated with new compounds

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:39:53 ON 25 OCT 2007

=> file reg
FILE 'REGISTRY' ENTERED AT 12:40:55 ON 25 OCT 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 23 OCT 2007 HIGHEST RN 951288-30-5
DICTIONARY FILE UPDATES: 23 OCT 2007 HIGHEST RN 951288-30-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=>
Uploading C:\Program Files\Stnexp\Queries\10525121.str



chain nodes :
7 8 10 11 12 13 14
ring nodes :
1 2 3 4 5 6
ring/chain nodes :
9 15
chain bonds :
1-10 4-7 7-8 8-9 10-11 11-12 11-13 12-14 14-15
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
1-2 1-6 1-10 2-3 3-4 4-5 4-7 5-6 7-8 8-9 10-11 11-12 11-13 12-14 14-15

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS 11:CLASS 12:CLASS 13:Atom 14:CLASS 15:CLASS

L1 STRUCTURE UPLOADED

=> que L1

L2 QUE L1

=> s l1
SAMPLE SEARCH INITIATED 12:41:34 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 3888 TO ITERATE

51.5% PROCESSED 2000 ITERATIONS 7 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 73865 TO 81335
PROJECTED ANSWERS: 50 TO 492

L3 7 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 12:41:39 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 76891 TO ITERATE

100.0% PROCESSED 76891 ITERATIONS 269 ANSWERS
SEARCH TIME: 00.00.03

L4 269 SEA SSS FUL L1

=> d scan

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Carbamic acid, [(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-, 2-methoxyethyl ester (9CI)
MF C29 H41 N3 O6 S
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):280

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4-Piperidinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-1-[(2-methoxyethoxy)acetyl]- (9CI)
MF C36 H52 N4 O7 S

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[(3S)-3-[[(3,3-difluorocyclobutyl)carbonyl]amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-, monohydrochloride (9CI)
MF C30 H39 F2 N3 O4 S . Cl H

Absolute stereochemistry.



● HCl

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[(3S)-3-[(3,5-difluorobenzoyl)amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-
MF C32 H37 F2 N3 O4 S
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 3-Pyridinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-1,6-dihydro-6-oxo- (9CI)
MF C31 H38 N4 O5 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI)
MF C33 H39 N5 O4 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylbutyl]- (9CI)
MF C32 H46 N4 O4 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[(1S)-3-[[(cyclohexylamino)carbonyl]amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[3-[(1-oxo-4-pentynyl)amino]-3-phenylpropyl]-4-piperidinyl]- (9CI)
MF C30 H39 N3 O4 S



PAGE 1-A

PAGE 1-B

—Me

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Carbamic acid, [(1S)-1-(3-fluorophenyl)-3-[4-[(phenylacetyl)amino]-1-piperidinyl]propyl]-, 1,1-dimethylethyl ester (9CI)
MF C27 H36 F N3 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[(1S)-3-[(cyclobutylcarbonyl)amino]-3-phenylpropyl]-4-piperidinyl]-4-methoxy- (9CI)
MF C28 H37 N3 O3

MF C32 H46 N4 O4 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4-Morpholinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI)
MF C30 H42 N4 O5 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1H-Benzimidazole-5-carboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI)
MF C33 H39 N5 O4 S

Absolute stereochemistry.

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[(3S)-3-[(cyclobutylcarbonyl)amino]-3-phenylpropyl]-4-piperidinyl]-4-fluoro-
MF C27 H34 F N3 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Carbamic acid, [(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-, 2-methylpropyl ester (9CI)
MF C30 H43 N3 O5 S
CI COM

Absolute stereochemistry.





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4-Thiomorpholinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI)
MF C30 H42 N4 O4 S2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[3-[[(methylthio)acetyl]amino]-3-phenylpropyl]-4-piperidinyl]- (9CI)
MF C28 H39 N3 O4 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4-Piperidinecarboxamide, 1-[[4-(acetylamino)phenyl]sulfonyl]-N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI)
MF C39 H51 N5 O7 S2

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Pyrrolidinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-3-fluoro-, (1S)- (9CI)
MF C30 H41 F N4 O4 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-ethyl-N-[1-[(3S)-1-methyl-3-phenyl-3-[(4,4,4-trifluoro-1-oxobutyl)amino]propyl]-4-piperidinyl]-4-(methylsulfonyl)-
MF C30 H40 F3 N3 O4 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[(3S)-3-[[3,5-difluorobenzoyl]amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-, monohydrochloride (9CI)
MF C32 H37 F2 N3 O4 S . Cl H

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[3-[(4-chlorobenzoyl)amino]-3-cyclohexylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-
MF C32 H44 Cl N3 O4 S

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT



● HCl

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1H-Pyrazole-5-carboxamide, 4-chloro-N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-1-methyl- (9CI)
MF C30 H38 Cl N5 O4 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-ethyl-N-[1-[(3S)-3-[(2-fluorobenzoyl)amino]-1-methyl-3-phenylpropyl]-4-piperidinyl]-4-(methylsulfonyl)-
MF C33 H40 F N3 O4 S

Absolute stereochemistry.



L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[3-[(2-cyclopenten-1-ylacetyl)amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)- (9CI)
MF C32 H43 N3 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[3-[(cyclohexylcarbonyl)amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-
MF C32 H45 N3 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Carbamic acid, [1-[3-chlorophenyl]-3-[4-[(phenylacetyl)amino]-1-piperidinyl]propyl]-, 1,1-dimethylethyl ester (9CI)
MF C27 H36 Cl N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[3-(benzoylmethylamino)-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-
MF C33 H41 N3 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI)
MF C31 H44 N4 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Carbamic acid, [(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-(3-fluorophenyl)propyl]-, 1,1-dimethylethyl ester (9CI)
MF C30 H42 F N3 O5 S

Absolute stereochemistry.

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[3-[(cyclobutylcarbonyl)amino]-3-phenylpropyl]-4-piperidinyl]-4-methoxy- (9CI)
MF C28 H37 N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2-Furancarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-5-(trifluoromethyl)- (9CI)
MF C31 H36 F3 N3 O5 S
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Carbamic acid, [(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-, 2-propenyl ester, monohydrochloride (9CI)
MF C29 H39 N3 O5 S . Cl H

Absolute stereochemistry.



● HCl

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4-Piperidinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-1-(ethylsulfonyl)- (9CI)
MF C33 H49 N4 O6 S2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-4-fluoro- (9CI)
MF C31 H43 F N4 O4 S

Absolute stereochemistry.

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-(2-thienyl)propyl]- (9CI)
MF C29 H42 N4 O4 S2

PAGE 1-A



PAGE 2-A





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-(3-fluorophenyl)propyl]- (9CI)
MF C31 H43 F N4 O4 S

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[(3R)-3-[(4-chlorobenzoyl)amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-
MF C32 H38 Cl N3 O4 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2H-Thiopyran-4-carboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]tetrahydro- (9CI)
MF C31 H43 N3 O4 S2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI)
MF C31 H44 N4 O4 S

Absolute stereochemistry.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2-Thiophenecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-5-(methylsulfonyl)- (9CI)
MF C31 H39 N3 O6 S3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2-Furancarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-5-methyl- (9CI)
MF C31 H39 N3 O5 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 3-Furancarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI)
MF C30 H37 N3 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[3-[[1-oxo-2-pentenyl]amino]-3-phenylpropyl]-4-piperidinyl]- (9CI)
MF C30 H41 N3 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2-Pyrrolidinecarboxamide, N-[3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-1-methyl- (9CI)
MF C31 H44 N4 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[(3S)-3-[(2,2-dimethyl-1-oxopropyl)amino]-3-

phenylpropyl]-4-piperidinyl)-4-fluoro- (9CI)
MF C27 H36 F N3 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[3-(3-chlorophenyl)-3-[(cyclobutylcarbonyl)amino]propyl]-4-piperidinyl]- (9CI)
MF C27 H34 Cl N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Carbamic acid, [(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-, 4-fluorophenyl ester (9CI)
MF C32 H38 F N3 O5 S
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4-Pyrimidinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-2-(methylthio)-, trifluoroacetate (9CI)
MF C31 H39 N5 O4 S2 . x C2 H F3 O2

CM 1

Absolute stereochemistry.



CM 2

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 5-Isoxazolecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-, trifluoroacetate (9CI)
MF C29 H36 N4 O5 S . x C2 H F3 O2

CM 1



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Carbamic acid, [(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-, phenylmethyl ester, monohydrochloride (9CI)
MF C33 H41 N3 O5 S . Cl H

Absolute stereochemistry.



● HCl

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4-Piperidinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-1-[(1-methylethyl)sulfonyl]- (9CI)
MF C34 H50 N4 O6 S2

Absolute stereochemistry.

Absolute stereochemistry.



CM 2

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 5-Isothiazolecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI)
MF C29 H36 N4 O4 S2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[3-phenyl-3-[[(propylamino)carbonyl]amino]propyl]-4-piperidinyl]-
MF C29 H42 N4 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[(1S)-3-phenyl-3-[[4,4,4-trifluoro-1-oxobutyl]amino]propyl]-4-piperidinyl]-
MF C29 H38 F3 N3 O4 S
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[(1S)-3-[[4-[(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-4-piperidinyl]-
MF C33 H42 N4 O6 S2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-ethyl-N-[1-[(1S)-3-[(2-fluorobenzoyl)amino]-3-phenylpropyl]-4-piperidinyl]-4-(methylsulfonyl)-
MF C32 H38 F N3 O4 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[(1S)-3-(benzoylamino)-3-(3-fluorophenyl)propyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-
MF C32 H38 F N3 O4 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Bicyclo[4.2.0]octa-1,3,5-triene-7-carboxamide, N-[1-(4-chlorophenyl)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]propyl]- (9CI)
MF C34 H40 Cl N3 O4 S

PAGE 1-A



PAGE 2-A

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-ethyl-N-[1-[3-[(3-methyl-1-oxo-2-pentenyl)amino]-3-phenylpropyl]-4-piperidinyl]-4-(methylsulfonyl)- (9CI)
MF C31 H43 N3 O4 S



● HCl

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4-Piperidinecarboxamide, 1-acetyl-N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI)
MF C33 H46 N4 O5 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1H-1,2,3-Triazole-4-carboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-5-(1-methylethyl)- (9CI)
MF C31 H42 N6 O4 S
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[(3-exo)-8-[(3S)-3-[(cyclopropylacetyl)amino]-3-phenylpropyl]-8-azabicyclo[3.2.1]oct-3-yl]-4-fluoro- (9CI)
MF C29 H36 F N3 O2

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[(3S)-3-[(cyclobutylcarbonyl)amino]-3-phenylpropyl]-4-piperidinyl]-α-methoxy-, (αR)- (9CI)
MF C28 H37 N3 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[(3S)-3-[[3-(methylsulfonyl)benzoyl]amino]-3-phenylpropyl]-4-piperidinyl]-
MF C33 H41 N3 O6 S2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Imidazo[2,1-b]thiazole-6-carboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI)
MF C31 H37 N5 O4 S2
CI COM

Absolute stereochemistry.

IN Benzeneacetamide, N-[1-[3-[(cyclobutylcarbonyl)amino]-3-phenylpropyl]-4-piperidinyl]-
MF C27 H35 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[(1S)-3-[(3,3-difluorocyclobutyl)carbonyl]amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-
MF C30 H39 F2 N3 O4 S
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Carbamic acid, [(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-, 2-methylpropyl ester, monohydrochloride (9CI)
MF C30 H43 N3 O5 S . Cl H

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1,2,3-Thiadiazole-4-carboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI)
MF C28 H35 N5 O4 S2
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4-Thiazolecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI)
MF C29 H36 N4 O4 S2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-ethyl-N-[1-[3-[[[(1-methylethyl)amino]carbonyl]amino]-3-phenylpropyl]-4-piperidinyl]-4-(methylsulfonyl)-
MF C29 H42 N4 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[(3S)-3-[[3-(4-chlorophenyl)-1-oxopropyl]amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)- (9CI)
MF C34 H42 Cl N3 O4 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

yl]amino]carbonyl]amino]propyl]-4-phenyl-4-piperidinyl]-, [1(S)]- (9CI)
MF C32 H36 Cl2 N4 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Carbamic acid, [(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-, phenyl ester (9CI)
MF C32 H39 N3 O5 S
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4-Piperidinecarboxamide, 1-(4-chlorobenzoyl)-N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI)
MF C38 H47 Cl N4 O5 S

Absolute stereochemistry.

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[(3S)-3-[[3-(4-cyanobenzoyl]amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-, monohydrochloride (9CI)
MF C33 H38 N4 O4 S . Cl H

Absolute stereochemistry.



● HCl

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1H-Indene-2-carboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-2,3-dihydro- (9CI)
MF C35 H43 N3 O4 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[3-[(1-oxo-6-heptynyl)amino]-3-phenylpropyl]-4-piperidinyl]- (9CI)
MF C32 H43 N3 O4 S

PAGE 1-A



PAGE 1-B

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[(3S)-3-[[(4,4-difluorocyclohexyl)carbonyl]amino]-1-methyl-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-, monohydrochloride (9CI)
MF C33 H45 F2 N3 O4 S . Cl H

Absolute stereochemistry.



● HCl

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 3-Pyridinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-4-(trifluoromethyl)- (9CI)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[[3-endo)-8-[[(3S)-3-[(cyclobutylcarbonyl)amino]-3-phenylpropyl]-8-azabicyclo[3.2.1]oct-3-yl]-4-fluoro- (9CI)
MF C29 H36 F N3 O2

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[(3S)-3-(3-fluorophenyl)-3-[[(1-hydroxycyclopentyl)carbonyl]amino]propyl]-4-piperidinyl]- (9CI)
MF C28 H36 F N3 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Acetamide, N-[1-[3-(3,4-dichlorophenyl)-3-[[[(2,3-dihydro-1H-inden-1-

MF C32 H37 F3 N4 O4 S
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1H-1,2,3-Triazole-4-carboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-5-(1-methylethyl)-, hydrochloride (9CI)
MF C31 H42 N6 O4 S . x Cl H

Absolute stereochemistry.



● x HCl

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1H-Pyrazole-3-carboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-1,5-dimethyl-, trifluoroacetate (9CI)
MF C31 H41 N5 O4 S . x C2 H F3 O2

CN 1

Absolute stereochemistry.



CN 2

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4-Morpholinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylbutyl]- (9CI)
MF C31 H44 N4 O5 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[3-cyclohexyl-3-[[(cyclohexylamino)carbonyl]amino]propyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-
MF C32 H52 N4 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[3-[(1,4-dioxopentyl)amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-
MF C30 H41 N3 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Carbamic acid, [(1S)-3-[4-[[[4-methoxyphenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-, 1,1-dimethylethyl ester (9CI)
MF C28 H39 N3 O4

Absolute stereochemistry.







PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[3-phenyl-3-[[[(1-phenylethyl)amino]carbonyl]amino]propyl]-4-piperidinyl]-
MF C34 H44 N4 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, 4-chloro-N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[3-[(cyclobutylcarbonyl)amino]-3-phenylpropyl]-4-methyl-4-piperidinyl]-4-methoxy- (9CI)
MF C29 H39 N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-[1-[3-(acetylamino)-1-oxo-3-(2-thienyl)propyl]-4-piperidinyl]-
MF C21 H25 N3 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[(3S)-3-[[(4,4-difluorocyclohexyl)carbonyl]amino]-3-(3,5-difluorophenyl)propyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-
MF C32 H41 F4 N3 O4 S
CI COM

Absolute stereochemistry.

α,α-dimethyl- (9CI)
MF C35 H44 Cl N3 O4 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[(3S)-3-[(difluoroacetyl)amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-, monohydrochloride (9CI)
MF C27 H35 F2 N3 O4 S . Cl H

Absolute stereochemistry.



● HCl

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[3-[(cyclobutylcarbonyl)amino]-3-phenylpropyl]-4-piperidinyl]-N-cyclopropyl-4-(methylsulfonyl)-
MF C31 H41 N3 O4 S





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4-Piperidinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-1-(phenylacetyl)- (9CI)
MF C39 H50 N4 O5 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[(1S)-3-[[(4,4-difluorocyclohexyl)carbonyl]amino]-3-(3,5-difluorophenyl)propyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-, monohydrochloride (9CI)
MF C32 H41 F4 N3 O4 S . Cl H

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



● HCl

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 3-Pyridinecarboxamide, 6-(acetylamino)-N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI)
MF C33 H41 N5 O3 S
CI COM

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4-Morpholinecarboxamide, N-[3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI)
MF C30 H42 N4 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4-Pyridinecarboxamide, 2-chloro-N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI)
MF C31 H37 Cl N4 O4 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4-Thiomorpholinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-, 1,1-dioxide (9CI)
MF C30 H42 N4 O6 S2

Absolute stereochemistry.

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2-Furancarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-5-(trifluoromethyl)-, monohydrochloride (9CI)
MF C31 H36 F3 N3 O5 S . Cl H

Absolute stereochemistry.



● HCl

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Imidazo[1,2-c]pyrimidine-2-carboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-5,6-dihydro-5-oxo- (9CI)
MF C32 H38 N6 O5 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[3-[(1-oxo-3-hexenyl)amino]-3-phenylpropyl]-4-piperidinyl]- (9CI)
MF C31 H43 N3 O4 S

PAGE 1-A



PAGE 1-B

—Me

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[3-[(cyclopropylcarbonyl)amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-
MF C29 H39 N3 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-ethyl-N-[1-[(1S)-3-[(4-fluorobenzoyl)amino]-1-methyl-3-phenylpropyl]-4-piperidinyl]-4-(methylsulfonyl)-
MF C33 H40 F N3 O4 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4-Morpholinecarboxamide, N-[3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-N-methyl- (9CI)
MF C31 H44 N4 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Carbamic acid, [1-(4-chlorophenyl)-3-[4-[(phenylacetyl)amino]-1-piperidinyl]propyl]-, 1,1-dimethylethyl ester (9CI) .
MF C27 H36 Cl N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[3-[(cyclobutylcarbonyl)amino]-3-phenylpropyl]-4-piperidinyl]-α-methyl-, (αS)- (9CI)
MF C28 H37 N3 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Acetamide, N-[4-[4-(acetylamino)-4-phenyl-1-piperidinyl]-2-(3,4-dichlorophenyl)-2-[[[(diphenylmethyl)amino]carbonyl]methylamino]butyl]-2,2-difluoro-N-methyl-
MF C41 H45 Cl2 F2 N5 O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4-Piperidinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI)
MF C31 H44 N4 O4 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4-Piperidinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-1-[(4-fluorophenyl)sulfonyl]- (9CI)
MF C37 H47 F N4 O6 S2

Absolute stereochemistry.

PAGE 1-A





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[(3S)-3-(benzoylamino)-1-methyl-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-
MF C33 H41 N3 O4 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4-Morpholinecarboxamide, N-[3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-(2-thienyl)propyl]- (9CI)
MF C28 H40 N4 O5 S2

PAGE 1-B

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Pyrrolidinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-3-fluoro-, (3R)- (9CI)
MF C30 H41 F N4 O4 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-ethyl-N-[1-[(3S)-1-methyl-3-phenyl-1-[(3,3,3-trifluoro-1-oxopropyl)amino]propyl]-4-piperidinyl]-4-(methylsulfonyl)-
MF C29 H38 F3 N3 O4 S

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-ethyl-N-[1-[(3S)-3-[(4-fluorobenzoyl)amino]-3-phenylpropyl]-4-piperidinyl]-4-(methylsulfonyl)-
MF C32 H38 F N3 O4 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1H-Pyrrole-2-carboxamide, 4-acetyl-3-cyano-N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-5-methyl-, trifluoroacetate (9CI)
MF C34 H41 N5 O5 S . x C2 H F3 O2

CN 1

Absolute stereochemistry.



CN 2

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2-Thiophenecarboxamide, 5-acetyl-N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI)
MF C32 H39 N3 O5 S2

Absolute stereochemistry.

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Carbamic acid, [3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-(2-thienyl)propyl]-, 1,1-dimethylethyl ester (9CI)
MF C28 H41 N3 O5 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Carbamic acid, [3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-, 1,1-dimethylethyl ester (9CI)
MF C30 H43 N3 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-ethyl-N-[1-[3-[(3-methyl-1-oxo-2-butenyl)amino]-3-phenylpropyl]-4-piperidinyl]-4-(methylsulfonyl)- (9CI)
MF C30 H41 N3 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[3-[(cyclobutylcarbonyl)amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-
MF C30 H41 N3 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Carbamic acid, [1-(4-methoxyphenyl)-3-[4-[[(4-methoxyphenyl)acetyl]amino]-1-piperidinyl]propyl]-, 1,1-dimethylethyl ester (9CI)
MF C29 H41 N3 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[3-(4-chlorophenyl)-3-[(cyclobutylcarbonyl)amino]propyl]-4-piperidinyl]- (9CI)
MF C27 H34 Cl N3 O2



PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1H-Pyrazole-5-carboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-1,3-dimethyl-, trifluoroacetate (9CI)
MF C31 H41 N5 O4 S . x C2 H F3 O2

CM 1

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[(3S)-3-[[(3,3-difluorocyclobutyl]carbonyl]amino]-3-(3,5-difluorophenyl)propyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-
MF C30 H37 F4 N3 O4 S
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Carbamic acid, [(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-, 2,2,2-trichloroethyl ester, monohydrochloride (9CI)
MF C28 H36 Cl3 N3 O5 S . Cl H

Absolute stereochemistry.



● HCl

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4-Piperidinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-1-[(phenylmethyl)sulfonyl]- (9CI)

CM 2

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Pyrazinecarboxylic acid, 3-[[[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]amino]carbonyl]-, methyl ester (9CI)
MF C32 H39 N5 O6 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 5-Thiazolecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI)
MF C29 H36 N4 O4 S2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

MF C38 H50 N4 O4 S2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[(3S)-3-[[(4,4-difluorocyclohexyl]carbonyl]amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-
MF C33 H43 F2 N3 O4 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2H-Pyran-4-carboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-(3-fluorophenyl)propyl]tetrahydro- (9CI)
MF C31 H42 F N3 O5 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[(3S)-3-[(4-chlorobenzoyl)amino]-1-methyl-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-
MF C33 H40 Cl N3 O4 S

Absolute stereochemistry.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-ethyl-N-[1-[(3S)-3-[(3-fluorobenzoyl)amino]-3-phenylpropyl]-4-piperidinyl]-4-(methylsulfonyl)-
MF C32 H38 F N3 O4 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[(3S)-3-[(3,3-dimethyl-1-oxobutyl)amino]-3-(3-fluorophenyl)propyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-
MF C31 H44 F N3 O4 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[(3S)-3-(benzoylamino)-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-
MF C32 H39 N3 O4 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-ethyl-N-[1-[3-[(2-methyl-1-oxo-4-pentenyl)amino]-3-phenylpropyl]-4-piperidinyl]-4-(methylsulfonyl)- (9CI)
MF C31 H43 N3 O4 S





● HCl

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4-Piperidinecarboxamide, N-[(1S)-3-[4-(ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-1-(phenylsulfonyl)- (9CI)
MF C37 H48 N4 O6 S2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[(3S)-3-[[4-cyanobenzoyl]amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-
MF C33 H38 N4 O4 S
CI COM

Absolute stereochemistry.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[3-[(cyclopentylacetyl)amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)- (9CI)
MF C33 H45 N3 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 3-Azetidinecarboxamide, 1-acetyl-N-[(1S)-3-[4-[[(4-fluorophenyl)acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI)
MF C28 H35 F N4 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[3-[(cyclobutylcarbonyl)amino]-3-(3,4-dichlorophenyl]propyl]-4-piperidinyl]-4-methoxy- (9CI)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-ethyl-N-[1-[(3S)-3-[[4-[(methylamino)sulfonyl]benzoyl]amino]-3-phenylpropyl]-4-piperidinyl]-4-(methylsulfonyl)-
MF C33 H42 N4 O6 S2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4-Pyrimidinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-2-(methylthio)- (9CI)
MF C31 H39 N5 O4 S2
CI COM

Absolute stereochemistry.

MF C28 H35 Cl2 N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Carbamic acid, [(1S)-3-[4-[ethyl[[4-(methylsulfonyl]phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-, 2,2,2-trichloroethyl ester (9CI)
MF C28 H36 Cl3 N3 O5 S
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Carbamic acid, [(1S)-3-[4-[ethyl[[4-(methylsulfonyl]phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-, phenyl ester, monohydrochloride (9CI)
MF C32 H39 N3 O5 S . Cl H

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 5-Isoxazolecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl]phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI)
MF C29 H36 N4 O5 S
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4-Oxazolecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl]phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-2-methyl- (9CI)
MF C30 H38 N4 O5 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[3-[[[(4-chlorophenyl)amino]carbonyl]amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-
MF C32 H39 Cl N4 O4 S



PAGE 1-A

PAGE 1-B

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[(3S)-3-[(3,3-dimethyl-1-oxobutyl)amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-
MF C31 H43 N3 O4 S

Absolute stereochemistry.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[3-(exo)-8-[(3S)-3-[(cyclobutylcarbonyl)amino]-3-phenylpropyl]-8-azabicyclo[3.2.1]oct-3-yl]-4-fluoro- (9CI)
MF C29 H36 F N3 O2

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[(2S,3R)-3-[(cyclobutylcarbonyl)amino]-2-methoxy-3-phenylpropyl]-4-piperidinyl]- (9CI)
MF C28 H37 N3 O3

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Carbamic acid, [3-[4-(acetylamino)-4-phenyl-1-piperidinyl]-1-(3,4-dichlorophenyl)propyl]-, (2-methoxyphenyl)methyl ester, (S)- (9CI)
MF C31 H35 Cl2 N3 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[(3S)-3-phenyl-3-[(4,4,4-trifluoro-1-oxobutyl)amino]propyl]-4-piperidinyl]-, monohydrochloride (9CI)
MF C29 H38 F3 N3 O4 S . Cl H

Absolute stereochemistry.



● HCl

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Bicyclo[4.2.0]octa-1,3,5-triene-7-carboxamide, N-[1-cyclohexyl-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]propyl]- (9CI)
MF C34 H47 N3 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Carbamic acid, [(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-, 2-propenyl ester (9CI)
MF C29 H39 N3 O5 S
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Carbamic acid, [(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-, 1,1-dimethylethyl ester (9CI)
MF C30 H43 N3 O5 S

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[3-[(3-cyclohexen-1-ylcarbonyl)amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-
MF C32 H43 N3 O4 S





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Carbamic acid, [(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-, 4-nitrophenyl ester (9CI)
MF C32 H38 N4 O7 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[(3S)-3-phenyl-3-[(4,4,4-trifluoro-2-methyl-1-oxobutyl)amino]propyl]-4-piperidinyl]-
MF C30 H40 F3 N3 O4 S
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[(3S)-3-[[4-(acetylamino)benzoyl]amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-
MF C34 H42 N4 O5 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 5-Pyrimidinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-4,6-dimethoxy-, trifluoroacetate (9CI)
MF C32 H41 N5 O6 S . x C2 H F3 O2

CM 1

Absolute stereochemistry.



CM 2

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1,2,4-Thiadiazole-3-carboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-, hydrochloride (9CI)
MF C28 H35 N5 O4 S2 . x Cl H

Absolute stereochemistry.



●x HCl

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1H-Pyrazole-3-carboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI)
MF C29 H37 N5 O4 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-ethyl-N-[1-[3-[[(ethylamino)carbonyl]amino]-3-phenylpropyl]-4-piperidinyl]-4-(methylsulfonyl)-
MF C28 H40 N4 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[(3S)-3-[[(2S)-1-oxo-2-phenylpropyl]amino]-3-phenylpropyl]-4-piperidinyl]-
MF C34 H43 N3 O4 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[(3S)-3-phenyl-3-[[3,3,3-trifluoro-1-oxopropyl]amino]propyl]-4-piperidinyl]-, monohydrochloride (9CI)
MF C28 H36 F3 N3 O4 S . Cl H

Absolute stereochemistry.



●HCl

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Bicyclo[4.2.0]octa-1,3,5-triene-7-carboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI)
MF C34 H41 N3 O4 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[3-[(1-exo-5-hexynyl)amino]-3-phenylpropyl]-4-piperidinyl]- (9CI)
MF C31 H41 N3 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[(3-endo)-8-[(3S)-3-[(cyclopropylacetyl)amino]-3-phenylpropyl]-8-azabicyclo[3.2.1]oct-3-yl]-4-fluoro- (9CI)
MF C29 H36 F N3 O2

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Pyrrolidinecarboxamide, N-[(1S)-1-(3-fluorophenyl)-3-[4-[(phenylacetyl)amino]-1-piperidinyl]propyl]- (9CI)
MF C27 H35 F N4 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Acetamide, N-[1-[3-(3,4-dichlorophenyl)-3-[[[[(2-methoxyphenyl)methyl]methylamino]carbonyl]amino]propyl]-4-phenyl-4-piperidinyl]-, (S)- (9CI)
MF C32 H38 Cl2 N4 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Carbamic acid, [(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-, 4-chlorophenyl ester (9CI)
MF C32 H38 Cl N3 O5 S
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4-Piperidinecarboxamide, 1-(cyclopropylcarbonyl)-N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI)
MF C35 H48 N4 O5 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[[1S]-3-[[(3,3-difluorocyclobutyl)carbonyl]amino]-3-(3-fluorophenyl)propyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-, monohydrochloride (9CI)
MF C30 H38 F3 N3 O4 S . Cl H

Absolute stereochemistry.



● HCl

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[(1S)-1-[(difluoroacetyl)amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)- (9CI)
MF C27 H35 F2 N3 O4 S
CI COM

Absolute stereochemistry.





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[3-phenyl-3-[[[(2-phenylethyl)amino]carbonyl]amino]propyl]-4-piperidinyl]-
MF C34 H44 N4 O4 S





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1H-Imidazole-4-carboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI)
MF C29 H37 N5 O4 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1H-Pyrazole-3-carboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-1,5-dimethyl- (9CI)
MF C31 H41 N5 O4 S
CI COM

Absolute stereochemistry.

—Me

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-α,α-dimethyl- (9CI)
MF C35 H45 N3 O4 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2H-Pyran-4-carboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]tetrahydro-2,2-dimethyl- (9CI)
MF C33 H47 N3 O5 S

Absolute stereochemistry.





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Pyrrolidinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylbutyl]- (9CI)
MF C31 H44 N4 O4 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[3-[[(cyclohexylamino)carbonyl]amino]-3-(2-thienyl)propyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-
MF C30 H44 N4 O4 S2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[3-[[(cyclobutylcarbonyl]amino]-3-phenylpropyl]-4-piperidinyl]-4-(methylsulfonyl)-N-2-propenyl- (9CI)
MF C31 H41 N3 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[3-[(1-oxo-4-pentenyl)amino]-3-phenylpropyl]-4-piperidinyl]- (9CI)
MF C30 H41 N3 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Carbamic acid, [(1S)-1-(3-fluorophenyl)-3-[4-[[(4-fluorophenyl)acetyl]amino]-1-piperidinyl]propyl]-, 1,1-dimethylethyl ester

(9CI)
MF C27 H35 F2 N3 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[3-[(cyclobutylcarbonyl)amino]-3-phenylpropyl]-4-piperidinyl]-4-methoxy-N-methyl- (9CI)
MF C29 H39 N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-[1-[(2S)-[[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]amino]phenylacetyl]-4-piperidinyl]-4-(trifluoromethyl)- (9CI)
MF C31 H37 F3 N4 O5

Absolute stereochemistry.





● HCl

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2-Pyridinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-4-methyl- (9CI)
MF C32 H40 N4 O4 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[(3S)-3-[(3,4-difluorobenzoyl)amino]-1-methyl-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-
MF C33 H39 F2 N3 O4 S

Absolute stereochemistry.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[(1S)-3-[[(3,3-difluorocyclobutyl)carbonyl]amino]-3-(3-fluorophenyl)propyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-
MF C30 H38 F3 N3 O4 S
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4-Piperidinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-1-(2-methyl-1-oxopropyl)- (9CI)
MF C35 H50 N4 O5 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[(1S)-3-[[(3,3-difluorocyclobutyl)carbonyl]amino]-3-(3,5-difluorophenyl)propyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-, monohydrochloride (9CI)
MF C30 H37 F4 N3 O4 S . Cl H

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[3-[(4-chlorobenzoyl)methylamino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-
MF C33 H40 Cl N3 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Pyrrolidinecarboxamide, N-[3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI)
MF C30 H42 N4 O4 S

PAGE 1-A





● HCl

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1,2,4-Thiadiazole-3-carboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI)
MF C28 H35 N5 O4 S2
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[(3S)-3-phenyl-3-[(4,4,4-trifluoro-2-methyl-1-oxobutyl)amino]propyl]-4-piperidinyl]-, monohydrochloride (9CI)
MF C30 H40 F3 N3 O4 S . Cl H

Absolute stereochemistry.

PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 3-Pyridinecarboxamide, 6-chloro-N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI)
MF C31 H37 Cl N4 O4 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-ethyl-N-[1-[(1S)-3-(3-fluorophenyl)-3-[(3,3,3-trifluoro-1-oxopropyl)amino]propyl]-4-piperidinyl]-4-(methylsulfonyl)-
MF C28 H35 F4 N3 O4 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[3-[(1-oxo-3-butenyl)amino]-3-phenylpropyl]-4-piperidinyl]- (9CI)
MF C29 H39 N3 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[3-[(cyclopentylcarbonyl)amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-
MF C31 H43 N3 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Carbamic acid, [1-(3-fluorophenyl)-3-[4-[(phenylacetyl)amino]-1-



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[(3-exo)-8-[(1S)-3-[[(4,4-difluorocyclohexyl)carbonyl]amino]-3-phenylpropyl]-8-azabicyclo[3.2.1]oct-3-yl]-N-ethyl-4-(methylsulfonyl)-
MF C34 H45 F2 N3 O4 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-ethyl-N-[1-[(1S)-3-[(3-hydroxy-3-methyl-1-oxobutyl)amino]-3-phenylpropyl]-4-piperidinyl]-4-(methylsulfonyl)-, monohydrochloride (9CI)
MF C30 H43 N3 O5 S . Cl H

Absolute stereochemistry.

piperidinyl]propyl]-, 1,1-dimethylethyl ester (9CI)
MF C27 H36 F N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[3-[(cyclobutylcarbonyl)amino]-3-phenylpropyl]-4-piperidinyl]-α-methyl-, (αR)- (9CI)
MF C28 H37 N3 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Acetamide, N-[4-[4-(acetylamino)-4-phenyl-1-piperidinyl]-2-(3,4-dichlorophenyl)-2-[[[(diphenylmethyl)amino]carbonyl]methylamino]butyl]-2,2-difluoro-N-methyl-, monohydrochloride (9CI)
MF C41 H45 Cl2 F2 N5 O3 . Cl H



● HCl



● HCl

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1H-Pyrrole-2-carboxamide, 4-acetyl-3-cyano-N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-5-methyl- (9CI)
MF C34 H41 N5 O5 S
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 3-Pyridinecarboxamide, 4-(acetylamino)-N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-, hydrochloride (9CI)
MF C33 H41 N5 O5 S . x Cl H

Absolute stereochemistry.

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Carbamic acid, [(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-, 4-chlorophenyl ester, monohydrochloride (9CI)
MF C32 H38 Cl N3 O5 S . Cl H

Absolute stereochemistry.



● HCl

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4-Piperidinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-1-[[4-(methylsulfonyl)phenyl]sulfonyl]- (9CI)
MF C38 H50 N4 O8 S3

Absolute stereochemistry.





●x HCl

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1H-Pyrrole-2-carboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI)
MF C30 H38 N4 O4 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Pyrrolidinecarboxamide, N-[3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-(2-thienyl)propyl]- (9CI)
MF C28 H40 N4 O4 S2

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[(3S)-3-[(4-chlorobenzoyl)amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-
MF C32 H38 Cl N3 O4 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

IN Benzeneacetamide, N-[1-[3-[(cyclobutylcarbonyl)amino]-3-(3-fluorophenyl)propyl]-4-piperidinyl]- (9CI)
MF C27 H34 F N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Carbamic acid, [(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-, phenylmethyl ester (9CI)
MF C33 H41 N3 O5 S
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Carbamic acid, [(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-, 4-fluorophenyl ester, monohydrochloride (9CI)
MF C32 H38 F N3 O5 S . Cl H

Absolute stereochemistry.

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Carbamic acid, [(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylbutyl]-, 1,1-dimethylethyl ester (9CI)
MF C31 H45 N3 O5 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[3-[[[(3-chlorophenyl)amino]carbonyl]amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-
MF C32 H39 Cl N4 O4 S

PAGE 1-A



PAGE 1-B

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[3-[(1-oxo-2-butenyl)amino]-3-phenylpropyl]-4-piperidinyl]- (9CI)
MF C29 H39 N3 O4 S



● HCl

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4-Piperidinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-1-(methylsulfonyl)- (9CI)
MF C32 H46 N4 O4 S2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-ethyl-N-[1-[(3S)-3-[(3-hydroxy-3-methyl-1-oxobutyl)amino]-3-phenylpropyl]-4-piperidinyl]-4-(methylsulfonyl)-
MF C30 H43 N3 O5 S
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2-Furancarboxamide, N-[3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]tetrahydro- (9CI)
MF C30 H41 N3 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[(3S)-3-[(cyclobutylcarbonyl)methylamino]-3-(3-fluorophenyl)propyl]-4-piperidinyl]-4-fluoro- (9CI)
MF C28 H35 F2 N3 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[(3S)-3-phenyl-3-[[4-(trifluoromethyl)benzoyl]amino]propyl]-4-piperidinyl]-
MF C33 H38 F3 N3 O4 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1H-Pyrazole-5-carboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-1,3-dimethyl- (9CI)
MF C31 H41 N5 O4 S
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1H-Pyrazole-3-carboxamide, 5-acetyl-N-[(1S)-3-[4-[ethyl[[4-[methylsulfonyl]phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-4-methyl- (9CI)
MF C32 H41 N5 O5 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1H-1,2,4-Triazole-3-carboxamide, N-[(1S)-3-[4-[ethyl[[4-[methylsulfonyl]phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI)
MF C29 H36 N6 O4 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[3-[(1-oxo-2-butynyl)amino]-3-phenylpropyl]-4-piperidinyl]- (9CI)
MF C29 H37 N3 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[3-(benzoylamino)-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-
MF C32 H39 N3 O4 S

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2-Pyridineacetamide, N-[1-[(3S)-3-[(cyclobutylcarbonyl)amino]-3-phenylpropyl]-4-piperidinyl]- (9CI)
MF C26 H34 N4 O2

Absolute stereochemistry.





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[3-[[[(1,1-dimethylethyl]amino]carbonyl]amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-
MF C30 H44 N4 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[(3S)-3-[(3,4-difluorobenzoyl)amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-
MF C32 H37 F2 N3 O4 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[3-[(cyclobutylcarbonyl]amino]-3-(4-methoxyphenyl]propyl]-4-piperidinyl]-4-methoxy- (9CI)
MF C29 H39 N3 O4

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[(1S)-3-[[(4,4-difluorocyclohexyl]carbonyl]amino]-1-methyl-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-
MF C33 H45 F2 N3 O4 S
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Carbamic acid, [(1S)-3-[4-[ethyl[[4-(methylsulfonyl]phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-, 2-methoxyethyl ester, monohydrochloride (9CI)
MF C29 H41 N3 O6 S . Cl H

Absolute stereochemistry.

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-ethyl-N-[1-[(3S)-3-[(3-fluorobenzoyl)amino]-3-(3-fluorophenyl)propyl]-4-piperidinyl]-4-(methylsulfonyl)-
MF C32 H37 F2 N3 O4 S

Absolute stereochemistry.





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Carbamic acid, [1-cyclohexyl-3-[4-[ethyl[[4-(methylsulfonyl]phenyl]acetyl]amino]-1-piperidinyl]propyl]-, 1,1-dimethylethyl ester (9CI)
MF C30 H49 N3 O5 S





● HCl

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[[[[(1S)-3-[4-[ethyl[[4-(methylsulfonyl]phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI)
MF C36 H52 N4 O6 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[(1S)-3-[(3-cyanobenzoyl)amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-
MF C33 H38 N4 O4 S
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[(1S)-3-[[4-(methylsulfonyl)benzoyl]amino]-3-phenylpropyl]-4-piperidinyl]-
MF C33 H41 N3 O6 S2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Imidazo[2,1-b]thiazole-6-carboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-, trifluoroacetate (9CI)
MF C31 H37 N5 O4 S2 . x C2 H F3 O2

CM 1

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2H-Pyran-4-carboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylbutyl]tetrahydro- (9CI)
MF C32 H45 N3 O5 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2H-Pyran-4-carboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]tetrahydro- (9CI)
MF C31 H43 N3 O5 S

Absolute stereochemistry.



CM 2

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1,2,3-Thiadiazole-4-carboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-, trifluoroacetate (9CI)
MF C28 H35 N5 O4 S2 . x C2 H F3 O2

CM 1

Absolute stereochemistry.



CM 2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[3-[(1-oxo-6-heptenyl)amino]-3-phenylpropyl]-4-piperidinyl]- (9CI)
MF C32 H45 N3 O4 S



PAGE 1-A

PAGE 1-B

—Me

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Carbamic acid, [(1S)-3-[(3-endo)-3-[[(4-fluorophenyl)acetyl]amino]-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl]-, 1,1-dimethylethyl ester (9CI)
MF C29 H39 F N3 O3

Absolute stereochemistry.

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1H-Imidazole-4-carboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-2-methyl- (9CI)
MF C30 H39 N5 O4 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[3-phenyl-3-[[(phenylamino)carbonyl]amino]propyl]-4-piperidinyl]-
MF C32 H40 N4 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-ethyl-N-[1-[(3S)-3-[[2-(4-fluorophenyl)-1-oxopropyl]amino]-3-phenylpropyl]-4-piperidinyl]-4-(methylsulfonyl)- (9CI)
MF C34 H42 F N3 O4 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2H-Pyran-4-carboxamide, N-[(1S)-1-(3-fluorophenyl)-3-[4-[(phenylacetyl)amino]-1-piperidinyl]propyl]tetrahydro- (9CI)
MF C28 H36 F N3 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzenepropanamide, N-[3-[4-(acetylamino)-4-phenyl-1-piperidinyl]-1-(3,4-dichlorophenyl)propyl]-2-methoxy-, (S)- (9CI)
MF C32 H37 Cl2 N3 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[(3S)-3-[[(3,3-difluorocyclobutyl)carbonyl]amino]-1-methyl-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-
MF C31 H41 F2 N3 O4 S
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4-Piperidinecarboxamide, 1-benzoyl-N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI)
MF C38 H48 N4 O5 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[(1S)-3-[(cyclopentylamino)carbonyl]amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-
MF C31 H44 N4 O4 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4-Isoxazolecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-5-methyl- (9CI)
MF C30 H38 N4 O5 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[(3S)-3-[[(3,3-difluorocyclobutyl)carbonyl]amino]-1-methyl-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-, monohydrochloride (9CI)
MF C31 H41 F2 N3 O4 S . Cl H

Absolute stereochemistry.



● HCl

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[(3S)-3-phenyl-3-[(3,3,3-trifluoro-1-oxopropyl)amino]propyl]-4-piperidinyl]-
MF C28 H36 F3 N3 O4 S
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-ethyl-N-[1-[3-[[(methylphenylamino)carbonyl]amino]-3-phenylpropyl]-4-piperidinyl]-4-(methylsulfonyl)-
MF C33 H42 N4 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-ethyl-N-[1-[(3S)-3-[[(2S)-3-methyl-1-oxo-2-phenylbutyl]amino]-3-phenylpropyl]-4-piperidinyl]-4-(methylsulfonyl)-
MF C36 H47 N3 O4 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[(3S)-3-[(4-cyanobenzoyl)amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-, monohydrochloride (9CI)
MF C33 H38 N4 O4 S . Cl H

Absolute stereochemistry.



● HCl

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 5-Pyrimidinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-4,6-dimethoxy- (9CI)
MF C32 H41 N5 O6 S
CI COM

Absolute stereochemistry.

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 3-Pyridinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-4-(trifluoromethyl)-, monohydrochloride (9CI)
MF C32 H37 F3 N4 O4 S . Cl H

Absolute stereochemistry.



● HCl

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Bicyclo[4.2.0]octa-1,3,5-triene-7-carboxamide, N-[3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI)
MF C34 H41 N3 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[3-[[3-(methylthio)-1-oxopropyl]amino]-3-phenylpropyl]-4-piperidinyl]-
MF C29 H41 N3 O4 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Carbamic acid, [1-(3,4-dichlorophenyl)-3-[4-[[(4-methoxyphenyl)acetyl]amino]-1-piperidinyl]propyl]-, 9H-fluoren-9-ylmethyl ester (9CI)
MF C38 H39 Cl2 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 9-Octadecenamide, N-[1-phenyl-2-[4-[(trifluoroacetyl)amino]-1-piperidinyl]ethyl]-, (Z)- (9CI)
MF C33 H52 F3 N3 O2

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> file caplus
FILE 'CAPLUS' ENTERED AT 12:43:30 ON 25 OCT 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907 - 25 Oct 2007 VOL 147 ISS 18
FILE LAST UPDATED: 24 Oct 2007 (20071024/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> d his

(FILE 'HOME' ENTERED AT 12:39:53 ON 25 OCT 2007)

FILE 'REGISTRY' ENTERED AT 12:40:55 ON 25 OCT 2007
L1 STRUCTURE UPLOADED
L2 0 L1
L3 7 S L1
L4 269 S L1 FULL

FILE 'CAPLUS' ENTERED AT 12:43:30 ON 25 OCT 2007

=> s l4
L5 16 L4

=> d chib abs hitstr 1-16

L5 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
2007:196880 Document No. 146:414331 Identification of Nonpeptide CCR5 Receptor Agonists by Structure-based Virtual Screening. Kellenberger, Esther; Springael, Jean-Yves; Parmentier, Marc; Hachet-Haas, Muriel; Galzi, Jean-Luc; Rognan, Didier (Bioinformatics of the Drug, CNRS UMR 7175-LC1, Illkirch, F-67400, Fr.). Journal of Medicinal Chemistry, 50(6), 1294-1303 (English) 2007. CODEN: JMCMAR. ISSN: 0022-2623. Publisher: American Chemical Society.

AB A three-dimensional model of the chemokine receptor CCR5 has been built to fulfill structural peculiarities of its 6-helix bundle and to distinguish known CCR5 antagonists from randomly chosen drug-like decoys. In silico screening of a library of 1.6 million com. available compds. against the CCR5 model by sequential filters (drug-likeness, 2-D pharmacophore, 3-D docking, scaffold clustering) yielded a hit list of 59 compds., out of which 10 exhibited a detectable binding affinity to the CCR5 receptor. Unexpectedly, most binders tested in a functional assay were shown to be agonists of the CCR5 receptor. A follow-up database query based on similarity to the most potent binders identified three new CCR5 agonists. Despite a moderate affinity of all nonpeptide ligands for the CCR5 receptor, one of the agonists was shown to promote efficient receptor internalization, which is a process therapeutically favorable for protection against HIV-1 infection.

IT 277744-94-7
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(identification of nonpeptide CCR5 receptor agonists by structure-based virtual screening in relation to HIV-1 virus infection treatment)

RN 277744-99-7 CAPLUS
CN Benzeneacetamide, N-[1-[3-[(cyclobutylcarbonyl)amino]-3-phenylpropyl]-4-piperidinyl]- (CA INDEX NAME)



L5 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
2006:1147789 Document No. 145:471850 Preparation of novel hydroxamic acid-containing amino acid derivatives as peptide deformylase inhibitors. Kang, Jae-Hoon; Lee, Hee-Yeol; An, Kyung-Mi; Cho, Bong-Hwan (Ildong Pharmaceutical Co., Ltd., S. Korea; Yu, Seung-Woo). PCT Int. Appl. WO 2006115353 A1 20061102, 54pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, NL, NR, NE, PL, PT, SE, SM, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2006-KR1500 20060421. PRIORITY: KR 2005-34057 20050425.

GI



AB The invention relates to novel peptide deformylase inhibitory compds. I [A is CONHOH or N(CHO)OH; R1 is H, alkyl, cycloalkyl, halo, or OH; R2 is H, alkyl, alkenyl, cycloalkyl, oxa/aza heterocyclyl, or benzyl; R3 is H, Me, alkyl, alkenyl, cycloalkyl, Ph, or benzyl; R4 is H, alkyl, alkenyl, hydroxycycloalkyl; Y is (un)substituted benzoyl, phenylacetyl, phenylsulfonyl, or phenylcarbamoyl] which have potent antibacterial activity. Thus, I [A is N(CHO)OH; R1, R4 are H; R2 is (R)-cyclopentylmethyl; R3 is (S)-tert-Bu; Y is p-(CF3)C6H4CO] was prepared by amidation reaction and showed MIC = 3.1 μg/mL against methicillin-resistant Staphylococcus aureus, which is comparable to that of vancomycin.

IT 913634-32-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hydroxamic acid-containing amino acid derivs. as peptide deformylase inhibitors)

RN 913634-32-9 CAPLUS
CN Benzamide, N-[1-[(3S)-[[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]amino]phenylacetyl]-4-piperidinyl]-4-(trifluoromethyl)- (9CI)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 269 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, N-[1-[(3R)-3-[(cyclobutylcarbonyl)amino]-3-phenylpropyl]-4-piperidinyl]-4-methoxy- (9CI)
MF C28 H37 N3 O3

Absolute stereochemistry. Rotation (+).

(CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
2006:757482 Document No. 145:337664 Overcoming hERG affinity in the discovery of the CCR5 antagonist maraviroc. Price, David A.; Armour, Duncan; De Groot, Marcel; Leishman, Derek; Napier, Carolyn; Perros, Manos; Stammen, Blanda L.; Wood, Anthony (Pfizer Global Research and Development, Sandwich Laboratories, Kent, CT13 9NJ, UK). Bioorganic & Medicinal Chemistry Letters, 16(17), 4613-4617 (English) 2006. CODEN: BMCLE8. ISSN: 0960-894X. Publisher: Elsevier B.V..

GI



AB The discovery of maraviroc (I) is described with particular reference to the generation of high selectivity over affinity for the hERG potassium channel. This was achieved through the use of a high throughput binding assay for the hERG channel that is known to show an excellent correlation with functional effects.

IT 910033-53-3
RL: PAC (Pharmacological activity); PREP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(overcoming hERG affinity in discovery of CCR5 antagonist maraviroc)

RN 910033-53-3 CAPLUS
CN Benzeneacetamide, N-[1-[(3S)-3-[(cyclobutylcarbonyl)amino]-3-phenylpropyl]-4-piperidinyl]-4-fluoro- (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
2005:120883 Document No. 142:219153 Preparation of (piperidylalkyl)benzylamine derivatives as tachykinin receptors antagonists. Nagasawa, Masaaki; Kawase, Nobuo; Tanaka, Nobuyuki; Nakamura, Hideki; Tsuzuike, Naoki; Murata, Masakazu (Zeria Pharmaceutical Co., Ltd., Japan). PCT Int. Appl. WO 2005012248 A1 20050210, 248 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2004-JP11065 20040802. PRIORITY: JP 2003-205114 20030731.

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. I [wherein X1 = NMe, NH, or O; X2 = a single bond, NH, CONH, O, S, etc.; X3 and X4 = independently H or halo; R1 = H, alkyl, (un)substituted Ph, etc.; R2 = H, alkyl, alkenyl, etc.; R3 = alkanoylamino, aminoalkanoyl, aminoalkanoylamino, etc.; R4 = H or forming a ring with R3; R5 = H or alkyl; m = 1 or 2; n = 0 or 1] or salts thereof are prepared as tachykinin receptors (NK) antagonists. For example, the compound II was prepared in a multi-step synthesis. II showed antagonistic activity with IC50 of 0.9 nM against human NK1. I are useful for the treatment of irritable bowel syndrome, pain, anxiety, obstructive bronchial diseases, headache, and vomiting (no data).

IT 841255-89-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of (piperidylalkyl)benzylamine derivs. as tachykinin receptors antagonists)

RN 841255-89-8 CAPLUS

CN Acetamide, N-[4-[4-(acetylamino)-4-phenyl-1-piperidinyl]-2-(3,4-dichlorophenyl)-2-[[[(diphenylmethyl)amino]carbonyl]methylamino]butyl]-2,2-difluoro-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



L5 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
2004:192841 Document No. 140:235610 Preparation of N-(4-piperidinyl) amide compounds as chemokine receptor CCR5 modulators. Cumming, John; Winter, Jon (AstraZeneca AB, Swed.). PCT Int. Appl. WO 2004018425 A1 20040304, 43 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2003-SE1287 20030819. PRIORITY: SE 2002-2483 20020821.

GI



I

AB The invention provides a compound of formula (I) [R1 = C1-6 alkoxy (optionally substituted by C1-4 alkoxy or phenyl), C3-6 alkenyloxy, PhO, piperidin-4-yl (1-substituted by COR7 or SO2R8); R2 = each (un)substituted Ph or heteroaryl, cycloalkyl; R2a, R4, R4a = H, C1-4 alkyl; R3, R3a = H, C1-4 alkyl, C1-4 alkoxy; R5 = H, (un)substituted C1-4 alkyl, C3-4 alkenyl, C3-4 alkynyl, C3-7 cycloalkyl; R6 = Ph, heteroaryl, PhNH, heteroarylNH, phenyl-C1-2 alkyl, heteroaryl-C1-2 alkyl, phenyl(C1-2 alkyl)NH, heteroaryl(C1-2 alkyl)NH; R7 = (un)substituted C1-6 alkyl ; R8 = C1-6 alkyl (optionally substituted by phenyl), phenyl; wherein the Ph and heteroaryl rings of any of the foregoing are independently optionally substituted by halo, cyano, nitro, hydroxy, C1-4 alkyl, C1-4 alkoxy, etc.; m, p, q = 0, 1, 2] or pharmaceutically acceptable salts thereof or solvates thereof. Also disclosed are compns. containing the compds. I, processes for preparing them, and a method of treating a chemokine mediated disease state in a warm blooded animal. The compds. I have activity as pharmaceuticals, in particular as modulators (such as agonists, partial agonists, inverse agonists or antagonists) of chemokine receptor (especially CCR5) activity, and may be used in the treatment of autoimmune, inflammatory, proliferative or hyperproliferative diseases, or immunol.-mediated diseases including rejection of transplanted organs or tissues (no data). They are also of value in inhibiting the entry of viruses such as human immunodeficiency virus (HIV) into target cells and, therefore, are of value in the prevention of infection by viruses such as HIV, the treatment of infection by viruses such as HIV and the prevention and/or treatment of acquired immune deficiency syndrome (AIDS). Thus, to a stirred solution of (S)-N-[1-(3-amino-3-phenylpropyl)piperidin-4-yl]-N- ethyl-2-(4-methanesulfonylphenyl)acetamide dihydrochloride (0.22 g, 0.42 mmol) in 5 mL CH2Cl2 was added N,N-diisopropylethylamine (0.75 mL), 1-acetylpiperidine-4-carboxylic acid (100 mg, 0.58 mmol), and O-(7-azabenzotriazol-1-yl)-N,N,N',N''-tetramethyluronium hexafluorophosphate (HATU) (300 mg) and the resulting mixture was stirred at room temperature for 18 h to give, after workup and silica gel chromatog., (S)-1-acetylpiperidine-4-carboxylic acid [3-[4-[ethyl[2-(4-methanesulfonylphenyl)acetyl]amino]piperidin-1-yl]-1-phenylpropyl]amide.

IT 667402-27-9P, (S)-Piperidine-4-carboxylic acid [3-[4-[ethyl[2-(4-methanesulfonylphenyl)acetyl]amino]piperidin-1-yl]-1-phenylpropyl]amide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of (4-piperidinyl) amide compds. as chemokine receptor CCR5 modulators for treating chemokine mediated disease)

RN 667402-27-9 CAPLUS

CN 4-Piperidinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 528586-29-0P, (S)-[3-[4-[Ethyl[2-(4-methanesulfonylphenyl)acetyl]amino]piperidin-1-yl]-1-(3-fluorophenyl)propyl]carbamic acid tert-butyl ester 667402-00-8P, (S)-1-Acetylpiperidine-4-carboxylic acid [3-[4-[ethyl[2-(4-methanesulfonylphenyl)acetyl]amino]piperidin-1-yl]-1-phenylpropyl]amide 667402-02-0P, (S)-1-(Benzenesulfonyl)piperidine-4-carboxylic acid [3-[4-[ethyl[2-(4-methanesulfonylphenyl)acetyl]amino]piperidin-1-yl]-1-phenylpropyl]amide 667402-03-1P, (S)-1-(Isopropylsulfonyl)piperidine-4-carboxylic acid [3-[4-[ethyl[2-(4-methanesulfonylphenyl)acetyl]amino]piperidin-1-yl]-1-phenylpropyl]amide 667402-04-2P, (S)-1-(Methanesulfonyl)piperidine-4-carboxylic acid [3-[4-[ethyl[2-(4-methanesulfonylphenyl)acetyl]amino]piperidin-1-yl]-1-phenylpropyl]amide 667402-05-3P, (S)-1-(Benzylsulfonyl)piperidine-4-carboxylic acid [3-[4-[ethyl[2-(4-methanesulfonylphenyl)acetyl]amino]piperidin-1-yl]-1-phenylpropyl]amide 667402-06-4P, (S)-1-(Ethanesulfonyl)piperidine-4-carboxylic acid [3-[4-[ethyl[2-(4-methanesulfonylphenyl)acetyl]amino]piperidin-1-yl]-1-phenylpropyl]amide 667402-07-5P, (S)-1-[[4-(Methylsulfonyl)phenyl]sulfonyl]piperidine-4-carboxylic acid [3-[4-[ethyl[2-(4-methanesulfonylphenyl)acetyl]amino]piperidin-1-yl]-1-phenylpropyl]amide 667402-08-6P, (S)-1-[(4-Fluorophenyl)sulfonyl]piperidine-4-carboxylic acid [3-[4-[ethyl[2-(4-methanesulfonylphenyl)acetyl]amino]piperidin-1-yl]-1-phenylpropyl]amide 667402-09-7P, (S)-1-[(4-Acetylaminophenyl)sulfonyl]piperidine-4-carboxylic acid [3-[4-[ethyl[2-(4-methanesulfonylphenyl)acetyl]amino]piperidin-1-yl]-1-phenylpropyl]amide 667402-10-0P, (S)-1-Isobutyrylpiperidine-4-carboxylic acid [3-[4-[ethyl[2-(4-methanesulfonylphenyl)acetyl]amino]piperidin-1-yl]-1-phenylpropyl]amide 667402-11-1P, (S)-1-(Phenylacetyl)piperidine-4-carboxylic acid [3-[4-[ethyl[2-(4-methanesulfonylphenyl)acetyl]amino]piperidin-1-yl]-1-phenylpropyl]amide 667402-13-3P, (S)-1-[(2-Methoxyethoxy)acetyl]piperidine-4-carboxylic acid [3-[4-[ethyl[2-(4-methanesulfonylphenyl)acetyl]amino]piperidin-1-yl]-1-phenylpropyl]amide 667402-14-4P, (S)-1-(Cyclopropylcarbonyl)piperidine-4-carboxylic acid [3-[4-[ethyl[2-(4-methanesulfonylphenyl)acetyl]amino]piperidin-1-yl]-1-phenylpropyl]amide 667402-15-5P, (S)-1-(4-Chlorobenzoyl)piperidine-4-carboxylic acid [3-[4-[ethyl[2-(4-methanesulfonylphenyl)acetyl]amino]piperidin-1-yl]-1-phenylpropyl]amide 667402-16-6P, (S)-1-Benzoylpiperidine-4-carboxylic acid [3-[4-[ethyl[2-(4-methanesulfonylphenyl)acetyl]amino]piperidin-1-yl]-1-phenylpropyl]amide 667402-18-8P, (S)-[3-[4-[Ethyl[2-(4-methanesulfonylphenyl)acetyl]amino]piperidin-1-yl]-1-phenylpropyl]carbamic acid isobutyl ester hydrochloride 667402-19-9P, (S)-[3-[4-[Ethyl[2-(4-methanesulfonylphenyl)acetyl]amino]piperidin-1-yl]-1-phenylpropyl]carbamic acid 2-methoxyethyl ester hydrochloride 667402-20-2P 667402-21-3P 667402-22-4P 667402-23-5P, (S)-[3-[4-[Ethyl[2-(4-methanesulfonylphenyl)acetyl]amino]piperidin-1-yl]-1-phenylpropyl]carbamic acid 2,2,2-trichloroethoxy ester hydrochloride 667402-24-6P, (S)-[3-[4-[Ethyl[2-(4-methanesulfonylphenyl)acetyl]amino]piperidin-1-yl]-1-phenylpropyl]carbamic acid allyl ester hydrochloride 667402-25-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (4-piperidinyl) amide compds. as chemokine receptor CCR5 modulators for treating chemokine mediated disease)

RN 528586-29-0 CAPLUS

CN Carbamic acid, [(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-(3-fluorophenyl)propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 667402-00-8 CAPLUS

CN 4-Piperidinecarboxamide, 1-acetyl-N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 667402-02-0 CAPLUS

CN 4-Piperidinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 667402-03-1 CAPLUS

CN 4-Piperidinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-1-[(1-methylethyl)sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 667402-04-2 CAPLUS

CN 4-Piperidinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 667402-05-3 CAPLUS

CN 4-Piperidinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-1-[(phenylmethyl)sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 667402-06-4 CAPLUS

CN 4-Piperidinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-1-(ethylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 667402-07-5 CAPLUS

CN 4-Piperidinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-1-[[4-(methylsulfonyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 667402-08-6 CAPLUS
CN 4-Piperidinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-1-[(4-fluorophenyl)sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 667402-15-5 CAPLUS
CN 4-Piperidinecarboxamide, 1-(4-chlorobenzoyl)-N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 667402-16-6 CAPLUS
CN 4-Piperidinecarboxamide, 1-benzoyl-N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 667402-09-7 CAPLUS
CN 4-Piperidinecarboxamide, 1-[[4-(acetylamino)phenyl]sulfonyl]-N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 667402-10-0 CAPLUS
CN 4-Piperidinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-1-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 667402-11-1 CAPLUS
CN 4-Piperidinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-1-(phenylacetyl)- (9CI) (CA INDEX NAME)



RN 667402-18-8 CAPLUS
CN Carbamic acid, [(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-, 2-methylpropyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 667402-19-9 CAPLUS
CN Carbamic acid, [(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-, 2-methoxyethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 667402-20-2 CAPLUS
CN Carbamic acid, [(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-

Absolute stereochemistry.



RN 667402-13-3 CAPLUS
CN 4-Piperidinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-1-[(2-methoxyethoxy)acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 667402-14-4 CAPLUS
CN 4-Piperidinecarboxamide, 1-(cyclopropylcarbonyl)-N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

piperidinyl]-1-phenylpropyl]-, phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 667402-21-3 CAPLUS
CN Carbamic acid, [(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-, phenylmethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 667402-22-4 CAPLUS
CN Carbamic acid, [(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-, 4-fluorophenyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 667402-23-5 CAPLUS
CN Carbamic acid, [(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-, 2,2,2-trichloroethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 667402-24-6 CAPLUS
CN Carbamic acid, [(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-, 2-propenyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

PIXED2. APPLICATION: WO 2003-SE480 20030324. PRIORITY: SE 2002-919 20020325.

GI



I

AB Title compds. [I; A = CH2CH2, null; R1 = C3-7 cycloalkyl, N-linked heterocyclyl (substituted by 1-3 F and optionally further substituted by alkyl); R2 = alkyl, cycloalkyl, Ph, heteroaryl optionally substituted by halo, alkyl, alkoxy, SOn(alkyl), NO2, cyano, CF3; R2a, R4, R4a = H, alkyl; R3, R3a = H, alkyl, alkoxy; R5 = H, alkyl optionally substituted by halo, OH, alkoxy, cycloalkyl, SH, alkylthio, cyano, SO2(alkyl), alkenyl, alkynyl, cycloalkyl; R6 = Ph, heteroaryl, PhNH, heteroarylNH, phenylalkyl, heteroarylalkyl, phenylalkylNH, heteroarylalkylNH; the Ph and heteroaryl rings of R6 are optionally substituted by halo, cyano, NO2, OH, alkyl, alkoxy, SO2NR7R8, NHSO2(alkyl), NH2, NH(alkyl), N(alkyl)2, NHCONH2, CONH2, COOH(alkyl), NHCO(alkyl), CO2H, CO2(alkyl), CO(alkyl), CF3, CHF2, CH2F, CH2CF3, OCF3, etc.; R7, R8 = H, alkyl, or together with a N or O atom may join to form a 5-6 membered ring which is optionally substituted with alkyl, CHO, CO(alkyl); m, n, q = 0-2], were prepared Thus, (S)-N-[1-(3-phenyl-3-aminopropyl)-4-piperidinyl]-N-ethyl-4- methanesulfonylphenylacetamide dihydrochloride (preparation given), 4,4-difluorocyclohexanecarboxylic acid, and N,N-diisopropylethylamine were stirred in CH2Cl2 at room temperature; HATU was added and stirring was continued for 16 h to give (S)-N-[1-(3-phenyl-3-(4,4-difluorocyclohexylcarboxyamino) propyl]-4-piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide. The latter inhibited binding of RANTES or MIP-1a to CCR5 receptors with -log IC50 = 8.95.

IT 607709-96-6P 607709-97-7P 607709-98-8P
607709-99-9P 607710-00-9P 607710-01-0P
607710-02-1P 607710-03-2P 607710-04-3P
607710-05-4P 607710-06-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of carbamoylpiperidines and carbamoylazabicyclooctanes useful as modulators of chemokine receptor (CCR5) activity)

RN 607709-96-6 CAPLUS
CN Benzeneacetamide, N-[1-[(3S)-3-[[(4,4-difluorocyclohexyl)carbonyl]amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.

RN 667402-25-7 CAPLUS
CN Carbamic acid, [(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-, 4-chlorophenyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 667402-01-9P, (S)-4-[[3-[4-[Ethyl[2-[4-(methanesulfonyl)phenyl]acetyl]amino]piperidin-1-yl]-1-phenylpropyl]carbamoyl]piperidine-1-carboxylic acid tert-butyl ester 667402-17-7P, (S)-[3-[4-[Ethyl[2-(4-methanesulfonylphenyl)acetyl]amino]piperidin-1-yl]-1-phenylpropyl]carbamic acid tert-butyl ester
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(reactant; preparation of (4-piperidinyl) amide compds. as chemokine receptor CCR5 modulators for treating chemokine mediated disease)

RN 667402-01-9 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 667402-17-7 CAPLUS
CN Carbamic acid, [(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 607709-97-7 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-4-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 607709-98-8 CAPLUS
CN Benzeneacetamide, N-[(3-exo)-8-[(3S)-3-[[(4,4-difluorocyclohexyl)carbonyl]amino]-3-phenylpropyl]-8-azabicyclo[3.2.1]oct-3-yl]-N-ethyl-4-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 607709-99-9 CAPLUS
CN 1-Pyrrolidinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-3-fluoro-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Absolute stereochemistry.



L5 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
2004:48671 Document No. 141:218285 Generation of predictive pharmacophore models for CCR5 antagonists: study with piperidine- and piperazine-based compounds as a new class of HIV-1 entry inhibitors. [Erratum to document cited in CA139:316613]. Debnath, Asim Kumar (Laboratory of Molecular Modeling & Drug Design, Lindsley F. Kimball Research Institute, The New York Blood Center, New York, NY, 10021, USA). Journal of Medicinal Chemistry, 47(3), 768 (English) 2004. CODEN: JMCHAR. ISSN: 0022-2623. Publisher: American Chemical Society.
AB In Table 6 on page 4512, the double-plus signs in the last column should be single-plus signs; the corrected table is given.
IT 277744-99-7
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(structure-activity relationship of piperidine- and piperazine-based compds. as new class of HIV-1 entry inhibitors and generation of predictive pharmacophore models for CCR5 antagonists (Erratum))
RN 277744-99-7 CAPLUS
CN Benzeneacetamide, N-[1-[3-[(cyclobutylcarbonyl)amino]-3-phenylpropyl]-4-piperidinyl]- (CA INDEX NAME)



L5 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
2003:777758 Document No. 139:282155 Preparation of carbamoylpiperidines and carbamoylazabicyclooctanes useful as modulators of chemokine receptor (CCR5) activity. Cumming, John (Astrazeneca AB, Swed.). PCT Int. Appl. WO 2003080574 A1 20031002, 45 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GH, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR (English). CODEN:



RN 607710-00-9 CAPLUS
CN 1-Pyrrolidinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-3-fluoro-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 607710-01-0 CAPLUS
CN Benzeneacetamide, N-[1-[(3S)-3-[[(3,3-difluorocyclobutyl)carbonyl]amino]-3-(3,5-difluorophenyl)propyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 607710-02-1 CAPLUS
CN Benzeneacetamide, N-[1-[(3S)-3-[[(4,4-difluorocyclohexyl)carbonyl]amino]-3-

(3,5-difluorophenyl]propyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



● HCl

RN 607710-03-2 CAPLUS
CN Benzeneacetamide, N-[1-[(3S)-3-[[(3,3-difluorocyclobutyl)carbonyl]amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 607710-04-3 CAPLUS
CN Benzeneacetamide, N-[1-[(3S)-3-[[(3,3-difluorocyclobutyl)carbonyl]amino]-3-(3-fluorophenyl]propyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 607710-05-4 CAPLUS
CN Benzeneacetamide, N-[1-[(3S)-3-[[4,4-difluorocyclohexyl]carbonyl]amino]-1-methyl-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 607710-06-5 CAPLUS
CN Benzeneacetamide, N-[1-[(3S)-3-[[(3,3-difluorocyclobutyl)carbonyl]amino]-1-methyl-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 528586-22-3P 528586-29-0P, (S)-[3-[4-[Ethyl[2-(4-methanesulfonylphenyl)acetyl]amino]piperidin-1-yl]-1-(3-fluorophenyl)propyl]carbamic acid tert-butyl ester 607710-07-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of carbamoylpiperidines and carbamoylazabicyclooctanes useful as modulators of chemokine receptor (CCR5) activity)

RN 528586-22-3 CAPLUS
CN Carbamic acid, [(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylbutyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528586-29-0 CAPLUS
CN Carbamic acid, [(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-(3-fluorophenyl)propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 607710-07-6 CAPLUS
CN Carbamic acid, [(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-, 4-nitrophenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
2003:727536 Document No. 139:316413 Generation of Predictive Pharmacophore Models for CCR5 Antagonists: Study with Piperidine- and Piperazine-Based Compounds as a New Class of HIV-1 Entry Inhibitors. Dalmath, Asim Kumar (Laboratory of Molecular Modeling & Drug Design, Lindsley F. Kimball Research Institute, The New York Blood Center, New York, NY, 10021, USA). Journal of Medicinal Chemistry, 46(21), 4501-4515 (English) 2003. CODEN: JMCMAR. ISSN: 0022-2623. Publisher: American Chemical Society.

AB Predictive pharmacophore models were developed for a large series of piperidine- and piperazine-based CCR5 antagonists as anti-HIV-1 agents reported by Schering-Plough Research Institute in recent years. The pharmacophore models were generated using a training set consisting of 25 carefully selected antagonists based on well documented criteria. The activity spread, expressed in Ki, of training set mols. was from 0.1 to 1300 nM. The most predictive pharmacophore model (hypothesis 1), consisting of five features, namely, two hydrogen bond acceptors and three hydrophobic, had a correlation (r) of 0.920 and a root mean square of 0.879, and the cost difference between null cost and fixed cost was 44.46 bits. The model was cross-validated by randomizing the data using the CatScramble technique. The results confirmed that the pharmacophore models generated from the test set were not due to chance correlation. The best model (hypothesis 1) was validated using test set mols. (total of 78) and performed well in classifying active and inactive mols. correctly. The model was further validated by mapping onto it a diverse set of six CCR5 antagonists identified by five different pharmaceutical companies. The best model correctly predicted these compds. as being highly active. These multiple validation approaches provide confidence in the utility of the predictive pharmacophore model developed in this study as a 3D query tool in virtual screening to retrieve new chemical entities as potent CCR5 antagonists. The model can also be used in predicting biol. activities of compds. prior to undertaking their costly synthesis.

IT 277744-99-7
RL: PAC (Pharmacological activity); PEP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(structure-activity relationship of piperidine- and piperazine-based compds. as a new class of HIV-1 entry inhibitors and generation of predictive pharmacophore models for CCR5 antagonists)

RN 277744-99-7 CAPLUS
CN Benzeneacetamide, N-[1-[3-[(cyclobutylcarbonyl)amino]-3-phenylpropyl]-4-piperidinyl]- (CA INDEX NAME)



L5 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
2003:396855 Document No. 138:395313 Preparation of N-piperidin-4-yl benzeneacetamides and their use as modulators of chemokine receptor activity (especially CCR5). Cumming, John (Astrazeneca A.B., Swed.). PCT Int. Appl. WO 2003042178 A1 20030522, 62 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SK, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2002-SE2056 20021113. PRIORITY: GB 2001-27547 20011116.

GI



AB N-piperidin-4-yl benzeneacetamides (shown as I; variables defined below; e.g. N-[(S)-1-(3-phenyl-3-benzoylaminopropyl)-4-piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide), compns. comprising them, processes for preparing them and their use in medical therapy (for example modulating CCR5 receptor activity in a warm blooded animal) are described. Inhibition by 30 examples of I of binding of MIP-1α to CCR5 are tabulated. Seven example prepns. of I and mass spectral parent ion masses for .apprx.100 examples of I are included. For example, To a mixture of (S)-N-[1-(3-phenyl-3-aminopropyl)-4-piperidinyl]-N-ethyl-4- methanesulfonylphenylacetamide dihydrochloride (0.42 mmol) and DIPEA (0.75 mL) in CH2Cl2 (5 mL) was added benzoic acid (0.82 mmol); to the resulting mixture was added HATU (300 mg); the mixture was left at room temperature for 18 h, washed with 2N aqueous sodium hydroxide and water, then evaporated; purification gave (S)-N-[1-(3-phenyl-3-benzoylaminopropyl)-4-piperidinyl]-N-ethyl-4- methanesulfonylphenylacetamide (144 mg). Five example pharmaceutical formulations containing I are described. For I: R1 is NHR8, C1-6 alkyl (optionally substituted with hydroxy or halo or phenyl), Ph, heteroaryl, an N-linked 5- or 6-membered nonarom. heterocyclic ring, or a nonarom., 5- or 6-membered monoheteroatom heterocyclic ring, the heteroatom being O or S (optionally substituted by C1-4-alkyl). R2 is H or C1-6 alkyl; R3 is Ph or heteroaryl, either of which is optionally substituted by halo, C1-4 alkyl, C1-4 alkoxy, S(O)nR(C1-4 alkyl), nitro, cyano or CF3; or R3 is C5-7 cycloalkyl. R4 is H or C1-4 alkyl; R5 is Et, allyl or cyclopropyl; R6 is H, halo, hydroxy, nitro, S(O)nR(C1-4 alkyl), S(O)2NR2, S(O)2NH(C1-4 alkyl), S(O)2N(C1-4 alkyl)2, cyano, C1-4 alkyl, C1-4 alkoxy, C(O)NR2, C(O)NH(C1-4alkyl), C(O)N(C1-4 alkyl)2, CO2H, CO2(C1-4 alkyl), NHC(O)(C1-4 alkyl), NHS(O)2(C1-4alkyl), C(O)(C1-4alkyl), CF3 or OCF3; k, m and n = 0, 1 or 2; R7 is C1-6 alkyl; addnl. details are given in the claims.

IT 528586-10-6P, (S)-N-[1-[3-Phenyl-3-[[(thiomorpholin-4-yl)carbonyl]amino]propyl]-4-piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of N-piperidinyl benzeneacetamides and their use as modulators of chemokine receptor activity (especially CCR5))

RN 528586-10-6 CAPLUS
CN 4-Thiomorpholinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 528585-94-8P, (S)-N-[1-(3-Phenyl-3-benzoylaminopropyl)-4-piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528585-96-0P, (S)-N-[1-(3-Phenyl-3-(piperidin-1-ylcarbonylamino)propyl]-4-piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528586-00-7P, N-[1-[3-Phenyl-3-[[[(3-chlorophenyl)amino]carbonyl]amino]propyl]-4-piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528586-04-1P, N-[1-(3-Cyclohexyl-3-(4-chlorobenzoylamino)propyl)-4-piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528586-07-4P, (S)-N-[1-[3-(3,3,3-Trifluoropropionylamino)-3-(3-fluorophenyl)propyl]piperidin-4-yl]-N-ethyl-2-(4-methanesulfonylphenyl)acetamide 528586-09-6P, N-[1-[(3S)-3-Phenyl-3-[[(1,1-dioxothiomorpholin-4-yl)carbonyl]amino]propyl]-4-piperidinyl]-N-ethyl-4-

methanesulfonylphenylacetamide 528586-11-0P,
(S)-N-[1-[3-Phenyl-3-[[(2,2-dimethyltetrahydropyran-4-
yl)carbonyl]amino]propyl]-4-piperidinyl]-N-ethyl-4-
methanesulfonylphenylacetamide 528586-12-1P,
(S)-N-[1-(3-Phenyl-3-difluoroacetylaminopropyl)-4-piperidinyl]-N-ethyl-4-
methanesulfonylphenylacetamide hydrochloride 528586-13-2P,
(S)-N-[1-[3-Phenyl-3-[[(4-trifluoromethylpyridin-3-
yl)carbonyl]amino]propyl]-4-piperidinyl]-N-ethyl-4-
methanesulfonylphenylacetamide hydrochloride 528586-14-3P,
(S)-N-[1-[3-Phenyl-3-(3,3,3-trifluoropropionylamino)propyl]-4-piperidinyl]-
N-ethyl-4-methanesulfonylphenylacetamide hydrochloride
528586-15-4P, (S)-N-[1-[3-Phenyl-3-(3-cyanobenzoylamino)propyl]-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide hydrochloride
528586-16-5P, (3'S)-N-[1-[1-Methyl-3-phenyl-3-(tetrahydropyran-4-
ylcarbonylamino)propyl]-4-piperidinyl]-N-ethyl-4-
methanesulfonylphenylacetamide 528586-17-6P,
(S)-N-[1-[3-Phenyl-1-(4,4,4-trifluorobutyrylamino)propyl]-4-piperidinyl]-N-
ethyl-4-methanesulfonylphenylacetamide hydrochloride 528586-18-7P
, (S)-N-[1-[3-(Benzoylamino)-3-(3-fluorophenyl)propyl]piperidin-4-yl]-N-
ethyl-2-(4-methanesulfonylphenyl)acetamide 528586-19-8P,
(S)-N-[1-[3-(3-Fluorobenzoylamino)-3-(3-fluorophenyl)propyl]piperidin-4-
yl]-N-ethyl-2-(4-methanesulfonylphenyl)acetamide 528586-20-1P,
(S)-N-[1-[3-(3,3-Dimethylbutyrylamino)-3-(3-fluorophenyl)propyl]piperidin-
4-yl]-N-ethyl-2-(4-methanesulfonylphenyl)acetamide 528586-21-2P,
(S)-N-[1-[3-Phenyl-3-[[(tetrahydrothiopyran-4-yl)carbonyl]amino]propyl]-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528586-30-3P
, N-[1-((3S)-1-Phenyl-3-[[(6-chloropyridin-3-yl)carbonyl]amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528586-31-4P
, N-[1-((3S)-3-Phenyl-3-[[(2-chloropyridin-4-yl)carbonyl]amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528586-32-5P
, N-[1-((3S)-3-Phenyl-3-[[(benzimidazol-5-yl)carbonyl]amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528586-33-6P
, N-[1-((3S)-3-Phenyl-3-[(2-methyl-2-phenylpropanoyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528586-34-7P
, N-[1-((3S)-3-Phenyl-3-[(2-(4-chlorophenyl)-2-
methylpropanoyl)amino]propyl)-4-piperidinyl]-N-ethyl-4-
methanesulfonylphenylacetamide 528586-35-8P,
N-[1-((3S)-3-Phenyl-3-[((2R)-3-methyl-2-phenylbutanoyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528586-36-9P
, N-[1-((3S)-3-Phenyl-3-[((2S)-2-phenylpropanoyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528586-37-0P
, N-[1-((3S)-3-Phenyl-3-[(2-(4-chlorophenyl)propanoyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528586-38-1P
, N-[1-((3S)-3-Phenyl-3-[(2-(4-fluorophenyl)propanoyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528586-39-2P
, N-[1-((3S)-3-Phenyl-3-[(3,3-dimethylbutanoyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528586-40-5P
, N-[1-((3S)-3-Phenyl-3-[[2-fluorobenzoyl]amino]propyl]-4-piperidinyl]-N-
ethyl-4-methanesulfonylphenylacetamide 528586-41-6P,
N-[1-((3S)-3-Phenyl-3-[[3-fluorobenzoyl]amino]propyl)-4-piperidinyl]-N-
ethyl-4-methanesulfonylphenylacetamide 528586-42-7P,
N-[1-((3S)-3-Phenyl-3-[[3-fluorobenzoyl)amino]propyl)-4-piperidinyl]-N-
ethyl-4-methanesulfonylphenylacetamide 528586-43-8P,
N-[1-((3S)-3-Phenyl-3-[[4-chlorobenzoyl)amino]propyl)-4-piperidinyl]-N-
ethyl-4-methanesulfonylphenylacetamide 528586-44-9P,
N-[1-((3S)-3-Phenyl-3-[[4-chlorobenzoyl)amino]propyl)-4-piperidinyl]-N-
ethyl-4-methanesulfonylphenylacetamide 528586-45-0P,
N-[1-((3S)-3-Phenyl-3-[[4-fluorobenzoyl)amino]propyl)-4-piperidinyl]-N-
ethyl-4-methanesulfonylphenylacetamide 528586-46-1P,
N-[1-(3-Phenyl-3-[(piperidin-1-yl)carbonyl]amino]propyl)-4-piperidinyl]-N-
ethyl-4-methanesulfonylphenylacetamide 528586-47-2P,
N-[1-(3-Phenyl-3-[(pyrrolidin-1-yl)carbonyl]amino]propyl)-4-piperidinyl]-
N-ethyl-4-methanesulfonylphenylacetamide 528586-48-3P,
N-[1-(3-Phenyl-3-[[(morpholin-4-yl)carbonyl]amino]propyl)-4-piperidinyl]-N-
ethyl-4-methanesulfonylphenylacetamide 528586-49-4P,
N-[1-((3S)-3-Phenyl-3-[[(morpholin-4-yl)carbonyl]amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528586-50-7P
, N-[1-(3-Phenyl-3-[[((2-phenylethyl)amino]carbonyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528586-51-8P
, N-[1-(3-Phenyl-3-[[((1-phenylethyl)amino)carbonyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528586-52-9P
, N-[1-(3-Phenyl-3-[((methyl)(phenyl)amino)carbonyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528586-53-0P
, N-[1-(3-Phenyl-3-[[(ethylamino)carbonyl)amino]propyl)-4-piperidinyl]-N-
ethyl-4-methanesulfonylphenylacetamide 528586-54-1P,
N-[1-(3-Phenyl-3-[[(isopropylamino)carbonyl)amino]propyl)-4-piperidinyl]-N-
ethyl-4-methanesulfonylphenylacetamide 528586-55-2P,
N-[1-(3-Phenyl-3-[((phenylamino)carbonyl)amino]propyl)-4-piperidinyl]-N-
ethyl-4-methanesulfonylphenylacetamide 528586-56-3P,
N-[1-(3-Phenyl-3-[(((4-chlorophenyl)amino)carbonyl)amino]propyl]-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528586-57-4P
, N-[1-(3-Phenyl-3-[[((propylamino)carbonyl)amino]propyl)-4-piperidinyl]-N-
ethyl-4-methanesulfonylphenylacetamide 528586-58-5P,
N-[1-(3-Phenyl-3-[[((tert-butyl)amino)carbonyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528586-59-6P
, N-[1-(3-Phenyl-3-phenyl-3-[[4-chlorobenzoyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528586-60-9P
, N-[1-(3-(Thien-2-yl)-3-[[(piperidin-1-yl)carbonyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528586-61-0P
, N-[1-(3-(Thien-2-yl)-3-[((pyrrolidin-1-yl)carbonyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528586-62-1P
, N-[1-(3-(Thien-2-yl)-3-[[(morpholin-4-yl)carbonyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528586-63-2P
, N-[1-(3-Phenyl-3-((benzoyl)(methyl)amino)propyl)-4-piperidinyl]-N-ethyl-
4-methanesulfonylphenylacetamide 528586-64-3P,
N-[1-(3-Phenyl-3-((4-chlorobenzoyl)(methyl)amino]propyl)-4-piperidinyl]-N-
ethyl-4-methanesulfonylphenylacetamide 528586-65-4P
, 528586-66-5P, N-[1-((3S)-3-Phenyl-3-[[(cyclohexylamino)carbonyl]am
ino]propyl)-4-piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide
528586-67-6P, N-[1-(3-(Thien-2-yl)-3-[[(cyclohexylamino)carbonyl]a
mino]propyl)-4-piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide
528586-68-7P, N-[1-(3-Cyclohexyl-3-[[(cyclohexylamino)carbonyl)ami
no]propyl)-4-piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide
528586-69-8P, N-[1-((3S)-3-Phenyl-3-[[(5-methyl)isoazol-4-
yl)carbonyl]amino]propyl)-4-piperidinyl]-N-ethyl-4-
methanesulfonylphenylacetamide 528586-70-1P,
N-[1-((3S)-3-Phenyl-3-[((pyrazol-3-yl)carbonyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528586-71-2P
, N-[1-((3S)-3-Phenyl-3-[((thiazol-4-yl)carbonyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528586-72-3P
, N-[1-((3S)-3-Phenyl-3-[[(2-methylimidazol-5-yl)carbonyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528586-73-4P
, N-[1-((3S)-3-Phenyl-3-[[(2-methyloxazol-4-yl)carbonyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528586-74-5P
, N-[1-((3S)-3-Phenyl-3-[[(isothiazol-5-yl)carbonyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528586-75-6P
, N-[1-((3S)-3-Phenyl-3-[((1,2,4-triazol-5-yl)carbonyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528586-76-7P
, N-[1-((3S)-3-Phenyl-3-[((thiazol-5-yl)carbonyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528586-77-8P
, N-[1-((3S)-3-Phenyl-3-[[(furan-3-yl)carbonyl]amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528586-78-9P
, N-[1-((3S)-3-Phenyl-3-[((pyrrol-2-yl)carbonyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528586-79-0P
, N-[1-((3S)-1-Methyl-3-phenyl-3-[benzoylamino]propyl)-4-piperidinyl]-N-
ethyl-4-methanesulfonylphenylacetamide 528586-80-1P,
N-[1-((3S)-1-Methyl-3-phenyl-3-[(2-fluorobenzoyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528586-81-2P
, N-[1-((3S)-1-Methyl-3-phenyl-3-[(3,4-difluorobenzoyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528586-82-3P
, N-[1-((3S)-1-Methyl-3-phenyl-3-[(4-fluorobenzoyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528586-83-4P
, N-[1-((3S)-1-Methyl-3-phenyl-3-[((piperidin-1-yl)carbonyl)amino]propyl)-
4-piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide
528586-84-5P, N-[1-((3S)-1-Methyl-3-phenyl-3-[(((pyrrolidin-1-
yl)carbonyl)amino]propyl)-4-piperidinyl]-N-ethyl-4-
methanesulfonylphenylacetamide 528586-85-6P,
N-[1-((3S)-1-Methyl-3-phenyl-3-[((morpholin-4-yl)carbonyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528586-86-7P
, N-[1-((3S)-3-Phenyl-3-[((cyclopentylamino)carbonyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528586-87-0P
528586-88-1P, N-[1-((3S)-3-Phenyl-3-[((1,2,3-thiadiazol-4-
yl)carbonyl)amino]propyl)-4-piperidinyl]-N-ethyl-4-
methanesulfonylphenylacetamide 528586-89-2P,
N-[1-((3S)-3-Phenyl-3-[((1,2,3-thiadiazol-4-yl)carbonyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide trifluoroacetate
528586-90-5P, N-[1-((3S)-3-Phenyl-3-[((isoxazol-5-
yl)carbonyl)amino]propyl)-4-piperidinyl]-N-ethyl-4-
methanesulfonylphenylacetamide 528586-91-6P,
N-[1-((3S)-3-Phenyl-3-[((isoxazol-5-yl)carbonyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide trifluoroacetate
528586-92-7P, N-[1-((3S)-3-Phenyl-3-[((5-acetyl-4-methylpyrazol-3-
yl)carbonyl)amino]propyl)-4-piperidinyl]-N-ethyl-4-
methanesulfonylphenylacetamide 528586-93-8P,
N-[1-((3S)-3-Phenyl-3-[((3-(methoxycarbonyl)pyrazin-2-
yl)carbonyl)amino]propyl)-4-piperidinyl]-N-ethyl-4-
methanesulfonylphenylacetamide 528586-94-9P,
N-[1-((3S)-3-Phenyl-3-[((5-methylfuran-2-yl)carbonyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528586-95-0P
, N-[1-((3S)-3-Phenyl-3-[[(4-(acetylamino)pyridin-3-
yl)carbonyl)amino]propyl)-4-piperidinyl]-N-ethyl-4-
methanesulfonylphenylacetamide hydrochloride 528586-96-1P,
N-[1-((3S)-3-Phenyl-3-[((5-acetylthien-2-yl)carbonyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528586-97-2P
, N-[1-((3S)-3-Phenyl-3-[[(4-chloro-1-methylpyrazol-5-
yl)carbonyl)amino]propyl)-4-piperidinyl]-N-ethyl-4-
methanesulfonylphenylacetamide 528586-98-3P,
N-[1-((3S)-3-Phenyl-3-[((4-methylpyridin-2-yl)carbonyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528586-99-4P
, N-[1-((3S)-3-Phenyl-3-[((5,6-dihydro-5-oxoimidazo[1,2-c]pyrimidin-2-
yl)carbonyl)amino]propyl)-4-piperidinyl]-N-ethyl-4-
methanesulfonylphenylacetamide 528587-00-0P,
N-[1-((3S)-3-Phenyl-3-[((1H-pyrrolo[2,3-c]pyridin-2-
yl)carbonyl)amino]propyl)-4-piperidinyl]-N-ethyl-4-
methanesulfonylphenylacetamide 528587-01-1P,
N-[1-((3S)-3-Phenyl-3-[[(1,5-dimethylpyrazol-3-yl)carbonyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528587-02-2P
, N-[1-((3S)-3-Phenyl-3-[[(1,5-dimethylpyrazol-3-yl)carbonyl)amino]propyl]-
4-piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide trifluoroacetate
528587-03-3P, N-[1-((3S)-3-Phenyl-3-[[(4,6-dimethoxypyrimidin-5-
yl)carbonyl)amino]propyl)-4-piperidinyl]-N-ethyl-4-
methanesulfonylphenylacetamide 528587-04-4P,
N-[1-((3S)-3-Phenyl-3-[((4,6-dimethoxypyrimidin-5-
yl)carbonyl)amino]propyl)-4-piperidinyl]-N-ethyl-4-
methanesulfonylphenylacetamide trifluoroacetate 528587-05-5P,
N-[1-((3S)-3-Phenyl-3-[((imidazol[2,1-b]thiazol-6-
yl)carbonyl)amino]propyl)-4-piperidinyl]-N-ethyl-4-
methanesulfonylphenylacetamide 528587-06-6P,
N-[1-((3S)-3-Phenyl-3-[((imidazo[2,1-b]thiazol-6-yl)carbonyl)amino]propyl]-
4-piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide trifluoroacetate
528587-07-7P, N-[1-((3S)-3-Phenyl-3-[[(2-(methylthio)pyrimidin-4-
yl)carbonyl]amino]propyl)-4-piperidinyl]-N-ethyl-4-
methanesulfonylphenylacetamide 528587-08-8P,
N-[1-((3S)-3-Phenyl-3-[[(2-(methylthio)pyrimidin-4-
yl)carbonyl]amino]propyl)-4-piperidinyl]-N-ethyl-4-
methanesulfonylphenylacetamide trifluoroacetate 528587-09-9P,
N-[1-((3S)-3-Phenyl-3-[((1,3-dimethylpyrazol-5-yl)carbonyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528587-10-2P
, N-[1-((3S)-3-Phenyl-3-[((1,3-dimethylpyrazol-5-yl)carbonyl)amino]propyl)-
4-piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide trifluoroacetate
528587-11-3P, N-[1-((3S)-3-Phenyl-3-[[(5-(methylsulfonyl)thien-2-
yl)carbonyl)amino]propyl)-4-piperidinyl]-N-ethyl-4-
methanesulfonylphenylacetamide 528587-13-5P,
N-[1-((3S)-3-Phenyl-3-[[(4-acetyl-3-cyano-5-methylpyrrol-2-
yl)carbonyl)amino]propyl)-4-piperidinyl]-N-ethyl-4-
methanesulfonylphenylacetamide trifluoroacetate 528587-14-6P,
N-[1-((3S)-3-Phenyl-3-[((3,5-difluorobenzoyl)amino]propyl)-4-piperidinyl]-N-
ethyl-4-methanesulfonylphenylacetamide hydrochloride 528587-15-7P
, N-[1-((3S)-3-Phenyl-3-[[4,4,4-trifluoro-2-methylbutanoyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide hydrochloride
528587-16-8P, N-[1-((3S)-3-Phenyl-3-[[(5-(trifluoromethyl)furan-2-
yl)carbonyl)amino]propyl)-4-piperidinyl]-N-ethyl-4-
methanesulfonylphenylacetamide hydrochloride 528587-17-9P,
N-[1-((3S)-3-Phenyl-3-[[(1,6-dihydro-6-oxopyridin-3-
yl)carbonyl)amino]propyl)-4-piperidinyl]-N-ethyl-4-
methanesulfonylphenylacetamide 528587-18-0P,
N-[1-((3S)-3-Phenyl-3-[((imidazol-5-yl)carbonyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528587-19-1P
, N-[1-((3S)-3-Phenyl-3-[[((4-isopropyl-1,2,3-triazol-5-
yl)carbonyl)amino]propyl)-4-piperidinyl]-N-ethyl-4-
methanesulfonylphenylacetamide hydrochloride 528587-20-4P,
N-[1-((3S)-3-Phenyl-3-[[(4-cyanobenzoyl)amino]propyl)-4-piperidinyl]-N-
ethyl-4-methanesulfonylphenylacetamide hydrochloride 528587-21-5P
, N-[1-((3S)-3-Phenyl-3-[[(4-(acetylamino)benzoyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528587-22-6P
, N-[1-((3S)-3-Phenyl-3-[[3-(methylsulfonyl)benzoyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528587-23-7P
, N-[1-((3S)-3-Phenyl-3-[[(4-(methylsulfonyl)benzoyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528587-24-8P
, N-[1-((3S)-3-Phenyl-3-[[(4-((methylamino)sulfonyl)benzoyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528587-25-9P
, N-[1-((3S)-3-Phenyl-3-[[(4-((methylsulfonyl)amino)benzoyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528587-26-0P
, N-[1-((3S)-3-Phenyl-3-[[(4-(trifluoromethyl)benzoyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528587-27-1P
, N-[1-((3S)-3-(3-Fluorophenyl)-3-[((tetrahydropyran-4-
yl)carbonyl)amino]propyl)-4-piperidinyl]-N-ethyl-4-
methanesulfonylphenylacetamide 528587-28-2P,
N-[1-((3S)-3-(3-Fluorophenyl)-3-[((piperidin-1-yl)carbonyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528587-29-3P
, N-[1-((3S)-3-Phenyl-3-[[(3-hydroxy-3-methylbutanoyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide hydrochloride
528587-30-6P, N-[1-((3S)-1-Methyl-3-phenyl-3-[(3,3,3-
trifluoropropionyl)amino]propyl)-4-piperidinyl]-N-ethyl-4-
methanesulfonylphenylacetamide 528587-31-7P,
N-[1-((3S)-1-Methyl-3-phenyl-3-[(4,4,4-trifluorobutanoyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528587-32-8P
528587-33-9P, N-[1-((3S)-3-Phenyl-3-[[(4-(acetylamino)pyridin-3-
yl)carbonyl]amino]propyl)-4-piperidinyl]-N-ethyl-4-
methanesulfonylphenylacetamide 528587-34-0P,
N-[1-((3S)-3-Phenyl-3-[(3,5-difluorobenzoyl)amino]propyl)-4-piperidinyl]-N-
ethyl-4-methanesulfonylphenylacetamide 528587-35-1P,
N-[1-((3S)-3-Phenyl-3-[(difluoroacetyl)amino]propyl)-4-piperidinyl]-N-
ethyl-4-methanesulfonylphenylacetamide 528587-36-2P,
N-[1-((3S)-3-Phenyl-3-[[(4-(trifluoromethyl)pyridin-3-
yl)carbonyl]amino]propyl)-4-piperidinyl]-N-ethyl-4-
methanesulfonylphenylacetamide 528587-37-3P,
N-[1-((3S)-3-Phenyl-3-[(3,3,3-trifluoropropanoyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528587-38-4P
, N-[1-((3S)-3-Phenyl-3-[(4,4,4-trifluoro-2-methylbutanoyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528587-40-8P
, N-[1-((3S)-3-Phenyl-3-[((4-isopropyl-1,2,3-triazol-5-
yl)carbonyl]amino]propyl)-4-piperidinyl]-N-ethyl-4-
methanesulfonylphenylacetamide 528587-41-9P,
(S)-N-[1-[3-Phenyl-3-(3-cyanobenzoylamino)propyl]-4-piperidinyl]-N-ethyl-4-
methanesulfonylphenylacetamide 528587-42-0P,
N-[1-((3S)-3-Phenyl-3-[[(4-cyanobenzoyl)amino]propyl]-4-piperidinyl]-N-
ethyl-4-methanesulfonylphenylacetamide 528587-43-1P,
N-[1-((3S)-3-Phenyl-3-[[(4,4,4-trifluorobutanoyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528587-44-2P
, N-[1-((3S)-3-Phenyl-3-[[3-hydroxy-3-methylbutanoyl)amino]propyl]-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide
KL: BIOL (Biological activity); RPW (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(drug candidate; preparation of N-piperidinyl benzeneacetamides and their
use as modulators of chemokine receptor activity (especially CCR5))

RN 528583-84-8 CAPLUS
CN Benzeneacetamide, N-[1-[(3S)-3-(benzoylamino)-3-phenylpropyl]-4-
piperidinyl]-N-ethyl-4-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.

RN 528585-98-0 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-
(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI)
(CA INDEX NAME)

, N-[1-((3S)-3-Phenyl-3-[((furan-3-yl)carbonyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528586-78-9P
, N-[1-((3S)-3-Phenyl-3-[((pyrrol-2-yl)carbonyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528586-79-0P
, N-[1-((3S)-1-Methyl-3-phenyl-3-[benzoylamino]propyl)-4-piperidinyl]-N-
ethyl-4-methanesulfonylphenylacetamide 528586-80-1P,
N-[1-((3S)-1-Methyl-3-phenyl-3-[(2-fluorobenzoyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528586-81-2P
, N-[1-((3S)-1-Methyl-3-phenyl-3-[(3,4-difluorobenzoyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528586-82-3P
, N-[1-((3S)-1-Methyl-3-phenyl-3-[(4-fluorobenzoyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528586-83-4P
, N-[1-((3S)-1-Methyl-3-phenyl-3-[((piperidin-1-yl)carbonyl)amino]propyl)-
4-piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide
528586-84-5P, N-[1-((3S)-1-Methyl-3-phenyl-3-[(((pyrrolidin-1-
yl)carbonyl)amino]propyl)-4-piperidinyl]-N-ethyl-4-
methanesulfonylphenylacetamide 528586-85-6P,
N-[1-((3S)-1-Methyl-3-phenyl-3-[((morpholin-4-yl)carbonyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528586-86-7P
, N-[1-((3S)-3-Phenyl-3-[((cyclopentylamino)carbonyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528586-87-0P
528586-88-1P, N-[1-((3S)-3-Phenyl-3-[((1,2,3-thiadiazol-4-
yl)carbonyl)amino]propyl)-4-piperidinyl]-N-ethyl-4-
methanesulfonylphenylacetamide 528586-89-2P,
N-[1-((3S)-3-Phenyl-3-[((1,2,3-thiadiazol-4-yl)carbonyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide trifluoroacetate
528586-90-5P, N-[1-((3S)-3-Phenyl-3-[((isoxazol-5-
yl)carbonyl)amino]propyl)-4-piperidinyl]-N-ethyl-4-
methanesulfonylphenylacetamide 528586-91-6P,
N-[1-((3S)-3-Phenyl-3-[((isoxazol-5-yl)carbonyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide trifluoroacetate
528586-92-7P, N-[1-((3S)-3-Phenyl-3-[((5-acetyl-4-methylpyrazol-3-
yl)carbonyl)amino]propyl)-4-piperidinyl]-N-ethyl-4-
methanesulfonylphenylacetamide 528586-93-8P,
N-[1-((3S)-3-Phenyl-3-[((3-(methoxycarbonyl)pyrazin-2-
yl)carbonyl)amino]propyl)-4-piperidinyl]-N-ethyl-4-
methanesulfonylphenylacetamide 528586-94-9P,
N-[1-((3S)-3-Phenyl-3-[((5-methylfuran-2-yl)carbonyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528586-95-0P
, N-[1-((3S)-3-Phenyl-3-[[(4-(acetylamino)pyridin-3-
yl)carbonyl)amino]propyl)-4-piperidinyl]-N-ethyl-4-
methanesulfonylphenylacetamide hydrochloride 528586-96-1P,
N-[1-((3S)-3-Phenyl-3-[((5-acetylthien-2-yl)carbonyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528586-97-2P
, N-[1-((3S)-3-Phenyl-3-[[(4-chloro-1-methylpyrazol-5-
yl)carbonyl)amino]propyl)-4-piperidinyl]-N-ethyl-4-
methanesulfonylphenylacetamide 528586-98-3P,
N-[1-((3S)-3-Phenyl-3-[((4-methylpyridin-2-yl)carbonyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528586-99-4P
, N-[1-((3S)-3-Phenyl-3-[((5,6-dihydro-5-oxoimidazo[1,2-c]pyrimidin-2-
yl)carbonyl)amino]propyl)-4-piperidinyl]-N-ethyl-4-
methanesulfonylphenylacetamide 528587-00-0P,
N-[1-((3S)-3-Phenyl-3-[((1H-pyrrolo[2,3-c]pyridin-2-
yl)carbonyl)amino]propyl)-4-piperidinyl]-N-ethyl-4-
methanesulfonylphenylacetamide 528587-01-1P,
N-[1-((3S)-3-Phenyl-3-[[(1,5-dimethylpyrazol-3-yl)carbonyl)amino]propyl)-4-
piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528587-02-2P
, N-[1-((3S)-3-Phenyl-3-[[(1,5-dimethylpyrazol-3-yl)carbonyl)amino]propyl]-
4-piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide trifluoroacetate
528587-03-3P, N-[1-((3S)-3-Phenyl-3-[[(4,6-dimethoxypyrimidin-5-

Absolute stereochemistry.

RN 528586-00-7 CAPLUS
CN Benzeneacetamide, N-[1-[3-[[[(3-chlorophenyl)amino]carbonyl]amino]-3-
phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)- (CA INDEX NAME)

PAGE 1-A

PAGE 1-B

RN 528586-04-1 CAPLUS
CN Benzeneacetamide, N-[1-[3-[(4-chlorobenzoyl)amino]-3-cyclohexylpropyl]-4-
piperidinyl]-N-ethyl-4-(methylsulfonyl)- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 528586-07-4 CAPLUS
CN Benzeneacetamide, N-ethyl-N-[1-[(3S)-3-(3-fluorophenyl)-3-[(3,3,3-trifluoro-1-oxopropyl)amino]propyl]-4-piperidinyl]-4-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 528586-09-6 CAPLUS
CN 4-Thiomorpholinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 528586-16-5 CAPLUS
CN 2H-Pyran-4-carboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylbutyl]tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528586-17-6 CAPLUS
CN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[(3S)-3-phenyl-3-[(4,4,4-trifluoro-1-oxobutyl)amino]propyl]-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 528586-18-7 CAPLUS
CN Benzeneacetamide, N-[1-[(3S)-3-(benzoylamino)-3-(3-fluorophenyl)propyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 528586-11-0 CAPLUS
CN 2H-Pyran-4-carboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]tetrahydro-2,2-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528586-12-1 CAPLUS
CN Benzeneacetamide, N-[1-[(3S)-3-[(difluoroacetyl)amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 528586-13-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-4-(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



RN 528586-19-8 CAPLUS
CN Benzeneacetamide, N-ethyl-N-[1-[(3S)-3-[(3-fluorobenzoyl)amino]-3-(3-fluorophenyl)propyl]-4-piperidinyl]-4-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 528586-20-1 CAPLUS
CN Benzeneacetamide, N-[1-[(3S)-3-[(3,3-dimethyl-1-oxobutyl)amino]-3-(3-fluorophenyl)propyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.

Absolute stereochemistry.



● HCl

RN 528586-14-3 CAPLUS
CN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[(3S)-3-phenyl-3-[(3,3,3-trifluoro-1-oxopropyl)amino]propyl]-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 528586-15-4 CAPLUS
CN Benzeneacetamide, N-[1-[(3S)-3-[(3-cyanobenzoyl)amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl



RN 528586-21-2 CAPLUS
CN 2H-Thiopyran-4-carboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528586-30-3 CAPLUS
CN 3-Pyridinecarboxamide, 6-chloro-N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528586-31-4 CAPLUS
CN 4-Pyridinecarboxamide, 2-chloro-N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528586-32-5 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528586-33-6 CAPLUS
CN Benzeneacetamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-α,α-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528586-34-7 CAPLUS
CN Benzeneacetamide, 4-chloro-N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-α,α-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528586-41-6 CAPLUS
CN Benzeneacetamide, N-[1-[(3S)-3-[(3,4-difluorobenzoyl)amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 528586-42-7 CAPLUS
CN Benzeneacetamide, N-ethyl-N-[1-[(3S)-3-[(3-fluorobenzoyl)amino]-3-phenylpropyl]-4-piperidinyl]-4-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 528586-43-8 CAPLUS
CN Benzeneacetamide, N-[1-[(3R)-3-[(4-chlorobenzoyl)amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 528586-35-8 CAPLUS
CN Benzeneacetamide, N-ethyl-N-[1-[(3S)-3-[[(2S)-3-methyl-1-oxo-2-phenylbutyl]amino]-3-phenylpropyl]-4-piperidinyl]-4-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 528586-36-9 CAPLUS
CN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[(3S)-3-[[(2S)-1-oxo-2-phenylpropyl]amino]-3-phenylpropyl]-4-piperidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 528586-37-0 CAPLUS
CN Benzeneacetamide, N-[1-[(3S)-3-[[2-(4-chlorophenyl)-1-oxopropyl]amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528586-44-9 CAPLUS
CN Benzeneacetamide, N-[1-[(3S)-3-[(4-chlorobenzoyl)amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 528586-45-0 CAPLUS
CN Benzeneacetamide, N-ethyl-N-[1-[(3S)-3-[(4-fluorobenzoyl)amino]-3-phenylpropyl]-4-piperidinyl]-4-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 528586-46-1 CAPLUS
CN 1-Piperidinecarboxamide, N-[3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI) (CA INDEX NAME)





RN 528586-38-1 CAPLUS
CN Benzeneacetamide, N-ethyl-N-[1-[(3S)-3-[[2-(4-fluorophenyl)-1-oxopropyl]amino]-3-phenylpropyl]-4-piperidinyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528586-39-2 CAPLUS
CN Benzeneacetamide, N-[1-[(3S)-3-[(3,3-dimethyl-1-oxobutyl)amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 528586-40-5 CAPLUS
CN Benzeneacetamide, N-ethyl-N-[1-[(3S)-3-[(2-fluorobenzoyl)amino]-3-phenylpropyl]-4-piperidinyl]-4-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.

RN 528586-47-2 CAPLUS
CN 1-Pyrrolidinecarboxamide, N-[3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 528586-48-3 CAPLUS
CN 4-Morpholinecarboxamide, N-[3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI) (CA INDEX NAME)



RN 528586-49-4 CAPLUS
CN 4-Morpholinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-[methylsulfonyl]phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528586-50-7 CAPLUS
CN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[3-phenyl-3-[[[(2-phenylethyl)amino]carbonyl]amino]propyl]-4-piperidinyl]- (CA INDEX NAME)



PAGE 1-B

RN 528586-51-8 CAPLUS
CN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[3-phenyl-3-[[[(1-phenylethyl)amino]carbonyl]amino]propyl]-4-piperidinyl]- (CA INDEX NAME)



RN 528586-52-9 CAPLUS



RN 528586-60-9 CAPLUS
CN 1-Piperidinecarboxamide, N-[3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-(2-thienyl)propyl]- (9CI) (CA INDEX NAME)



PAGE 2-A



RN 528586-61-0 CAPLUS
CN 1-Pyrrolidinecarboxamide, N-[3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-(2-thienyl)propyl]- (9CI) (CA INDEX NAME)

CN Benzeneacetamide, N-ethyl-N-[1-[3-[[(methylphenylamino)carbonyl]amino]-3-phenylpropyl]-4-piperidinyl]-4-(methylsulfonyl)- (CA INDEX NAME)



RN 528586-53-0 CAPLUS
CN Benzeneacetamide, N-ethyl-N-[1-[3-[[(ethylamino)carbonyl]amino]-3-phenylpropyl]-4-piperidinyl]-4-(methylsulfonyl)- (CA INDEX NAME)



RN 528586-54-1 CAPLUS
CN Benzeneacetamide, N-ethyl-N-[1-[3-[[[[(1-methylethyl)amino]carbonyl]amino]-3-phenylpropyl]-4-piperidinyl]-4-(methylsulfonyl)- (CA INDEX NAME)



RN 528586-55-2 CAPLUS
CN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[3-phenyl-3-[[(phenylamino)carbonyl]amino]propyl]-4-piperidinyl]- (CA INDEX NAME)



RN 528586-56-3 CAPLUS
CN Benzeneacetamide, N-[1-[3-[[[(4-chlorophenyl)amino]carbonyl]amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 528586-62-1 CAPLUS
CN 4-Morpholinecarboxamide, N-[3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-(2-thienyl)propyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-A



PAGE 1-B

RN 528586-57-4 CAPLUS
CN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[3-phenyl-3-[[(propylamino)carbonyl]amino]propyl]-4-piperidinyl]- (CA INDEX NAME)



RN 528586-58-5 CAPLUS
CN Benzeneacetamide, N-[1-[3-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)- (CA INDEX NAME)



RN 528586-59-6 CAPLUS
CN Benzeneacetamide, N-[1-[(1S)-3-[(4-chlorobenzoyl)amino]-1-methyl-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 2-A



RN 528586-63-2 CAPLUS
CN Benzeneacetamide, N-[1-[3-(benzoylmethylamino)-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)- (CA INDEX NAME)



RN 528586-64-3 CAPLUS
CN Benzeneacetamide, N-[1-[3-[(4-chlorobenzoyl)methylamino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)- (CA INDEX NAME)



RN 528586-65-4 CAPLUS
CN 4-Morpholinecarboxamide, N-[3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 528586-66-5 CAPLUS
CN Benzeneacetamide, N-[1-[(3S)-3-[[(cyclohexylamino)carbonyl]amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 528586-67-6 CAPLUS
CN Benzeneacetamide, N-[1-[3-[[(cyclohexylamino)carbonyl]amino]-3-(2-thienyl)propyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 528586-68-7 CAPLUS
CN Benzeneacetamide, N-[1-[3-cyclohexyl-3-[[(cyclohexylamino)carbonyl]amino]propyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)- (CA INDEX NAME)



RN 528586-74-5 CAPLUS
CN 5-Isothiazolecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528586-75-6 CAPLUS
CN 1H-1,2,4-Triazole-3-carboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528586-76-7 CAPLUS
CN 5-Thiazolecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 528586-69-8 CAPLUS
CN 4-Isoxazolecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528586-70-1 CAPLUS
CN 1H-Pyrazole-3-carboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528586-77-8 CAPLUS
CN 3-Furancarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528586-78-9 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528586-79-0 CAPLUS
CN Benzeneacetamide, N-[1-[(3S)-3-(benzoylamino)-1-methyl-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 528586-71-2 CAPLUS
CN 4-Thiazolecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528586-72-3 CAPLUS
CN 1H-Imidazole-4-carboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528586-73-4 CAPLUS
CN 4-Oxazolecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528586-80-3 CAPLUS
CN Benzeneacetamide, N-ethyl-N-[1-[(3S)-3-[(2-fluorobenzoyl)amino]-1-methyl-3-phenylpropyl]-4-piperidinyl]-4-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 528586-81-4 CAPLUS
CN Benzeneacetamide, N-[1-[(3S)-3-[(3,4-difluorobenzoyl)amino]-1-methyl-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 528586-82-5 CAPLUS
CN Benzeneacetamide, N-ethyl-N-[1-[(3S)-3-[(4-fluorobenzoyl)amino]-1-methyl-3-phenylpropyl]-4-piperidinyl]-4-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 528586-83-6 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylbutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528586-84-7 CAPLUS
CN 1-Pyrrolidinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylbutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528586-85-8 CAPLUS
CN 4-Morpholinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylbutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528586-91-6 CAPLUS
CN 5-Isoxazolecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 528586-90-5
CMF C29 H36 N4 O5 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 528586-92-7 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-acetyl-N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528586-86-9 CAPLUS
CN Benzeneacetamide, N-[1-[(3S)-3-[[(cyclopentylamino)carbonyl]amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 528586-87-0 CAPLUS
CN 1,2,4-Thiadiazole-3-carboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● x HCl

RN 528586-88-1 CAPLUS
CN 1,2,3-Thiadiazole-4-carboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528586-93-8 CAPLUS
CN Pyrazinecarboxylic acid, 3-[[[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528586-94-9 CAPLUS
CN 2-Furancarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528586-95-0 CAPLUS
CN 3-Pyridinecarboxamide, 6-(acetylamino)-N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528586-89-2 CAPLUS
CN 1,2,3-Thiadiazole-4-carboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 528586-88-1
CMF C28 H35 N5 O4 S2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 528586-90-5 CAPLUS
CN 5-Isoxazolecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● x HCl

RN 528586-96-1 CAPLUS
CN 2-Thiophenecarboxamide, 5-acetyl-N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528586-97-2 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 4-chloro-N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-1-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528586-98-3 CAPLUS
CN 2-Pyridinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528586-99-4 CAPLUS
CN Imidazo[1,2-c]pyrimidine-2-carboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-5,6-dihydro-5-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528587-00-0 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528587-01-1 CAPLUS
CN 1H-Pyrazole-3-carboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-1,5-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528587-05-5 CAPLUS
CN Imidazo[2,1-b]thiazole-6-carboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CN 1

CRN 528587-05-5
CMF C31 H37 N5 O4 S2

Absolute stereochemistry.



CN 2

CRN 76-05-1
CMF C2 H F3 O2

RN 528587-07-7 CAPLUS
CN 4-Pyrimidinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-2-(methylthio)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528587-02-2 CAPLUS
CN 1H-Pyrazole-3-carboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-1,5-dimethyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CN 1

CRN 528587-01-1
CMF C31 H41 N5 O4 S

Absolute stereochemistry.



CN 2

CRN 76-05-1
CMF C2 H F3 O2

RN 528587-03-3 CAPLUS
CN 5-Pyrimidinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-4,6-dimethoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528587-08-8 CAPLUS
CN 4-Pyrimidinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-2-(methylthio)-, trifluoroacetate (9CI) (CA INDEX NAME)

CN 1

CRN 528587-07-7
CMF C31 H39 N5 O4 S2

Absolute stereochemistry.



CN 2

CRN 76-05-1
CMF C2 H F3 O2

RN 528587-09-9 CAPLUS
CN 1H-Pyrazole-5-carboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-1,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528587-04-4 CAPLUS
CN 5-Pyrimidinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-4,6-dimethoxy-, trifluoroacetate (9CI) (CA INDEX NAME)

CN 1

CRN 528587-03-3
CMF C32 H41 N5 O6 S

Absolute stereochemistry.



CN 2

CRN 76-05-1
CMF C2 H F3 O2

RN 528587-05-5 CAPLUS
CN Imidazo[2,1-b]thiazole-6-carboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528587-10-2 CAPLUS
CN 1H-Pyrazole-5-carboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-1,3-dimethyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CN 1

CRN 528587-09-9
CMF C31 H41 N5 O4 S

Absolute stereochemistry.



CN 2

CRN 76-05-1
CMF C2 H F3 O2

RN 528587-11-3 CAPLUS
CN 2-Thiophenecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528587-13-5 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-acetyl-3-cyano-N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-5-methyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 528587-12-4
CMF C34 H41 N5 O5 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 528587-14-6 CAPLUS
CN Benzeneacetamide, N-[1-[(3S)-3-[(3,5-difluorobenzoyl)amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 528587-20-4 CAPLUS
CN Benzeneacetamide, N-[1-[(3S)-3-[(4-cyanobenzoyl)amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 528587-21-5 CAPLUS
CN Benzeneacetamide, N-[1-[(3S)-3-[[4-(acetylamino)benzoyl]amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.

RN 528587-22-6 CAPLUS
CN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[(1S)-3-[[3-(methylsulfonyl)benzoyl]amino]-3-phenylpropyl]-4-piperidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 528587-15-7 CAPLUS
CN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[(1S)-3-phenyl-3-[[4,4,4-trifluoro-2-methyl-1-oxobutyl]amino]propyl]-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 528587-16-8 CAPLUS
CN 2-Furancarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-5-(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl



RN 528587-23-7 CAPLUS
CN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[(1S)-3-[[4-(methylsulfonyl]benzoyl]amino]-3-phenylpropyl]-4-piperidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 528587-24-8 CAPLUS
CN Benzeneacetamide, N-ethyl-N-[1-[(1S)-3-[[4-[(methylamino)sulfonyl]benzoyl]amino]-3-phenylpropyl]-4-piperidinyl]-4-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 528587-25-9 CAPLUS
CN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[(1S)-3-[[4-[(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-4-piperidinyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN 528587-17-9 CAPLUS
CN 3-Pyridinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-1,6-dihydro-6-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528587-18-0 CAPLUS
CN 1H-Imidazole-4-carboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528587-19-1 CAPLUS
CN 1H-1,2,3-Triazole-4-carboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-5-(1-methylethyl)-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● x HCl



RN 528587-26-0 CAPLUS
CN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[(3S)-3-phenyl-3-[[4-(trifluoromethyl)benzoyl]amino]propyl]-4-piperidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 528587-27-1 CAPLUS
CN 2H-Pyran-4-carboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-(3-fluorophenyl)propyl]tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 528587-28-2 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-(3-fluorophenyl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 528587-29-3 CAPLUS
CN Benzeneacetamide, N-ethyl-N-[1-[(1S)-3-[(3-hydroxy-3-methyl-1-oxobutyl)amino]-3-phenylpropyl]-4-piperidinyl]-4-(methylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528587-36-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528587-37-3 CAPLUS
CN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[(1S)-3-phenyl-3-[(3,3,3-trifluoro-1-oxopropyl)amino]propyl]-4-piperidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 528587-38-4 CAPLUS
CN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[(1S)-3-phenyl-3-[(4,4,4-trifluoro-2-methyl-1-oxobutyl)amino]propyl]-4-piperidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 528587-30-6 CAPLUS
CN Benzeneacetamide, N-ethyl-N-[1-[(1S)-1-methyl-3-phenyl-3-[(3,3,3-trifluoro-1-oxopropyl)amino]propyl]-4-piperidinyl]-4-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 528587-31-7 CAPLUS
CN Benzeneacetamide, N-ethyl-N-[1-[(1S)-1-methyl-3-phenyl-3-[(4,4,4-trifluoro-1-oxobutyl)amino]propyl]-4-piperidinyl]-4-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 528587-32-8 CAPLUS
CN 1,2,4-Thiadiazole-3-carboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI) (CA INDEX NAME)



RN 528587-40-8 CAPLUS
CN 1H-1,2,3-Triazole-4-carboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-5-(1-methylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528587-41-9 CAPLUS
CN Benzeneacetamide, N-[1-[(1S)-3-[(3-cyanobenzoyl)amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 528587-42-0 CAPLUS
CN Benzeneacetamide, N-[1-[(1S)-3-[(4-cyanobenzoyl)amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.

Absolute stereochemistry.



RN 528587-33-9 CAPLUS
CN 3-Pyridinecarboxamide, 6-(acetylamino)-N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528587-34-0 CAPLUS
CN Benzeneacetamide, N-[1-[(1S)-3-[(3,5-difluorobenzoyl)amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 528587-35-1 CAPLUS
CN Benzeneacetamide, N-[1-[(1S)-3-[(difluoroacetyl)amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528587-43-1 CAPLUS
CN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[(1S)-3-phenyl-3-[(4,4,4-trifluoro-1-oxobutyl)amino]propyl]-4-piperidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 528587-44-2 CAPLUS
CN Benzeneacetamide, N-ethyl-N-[1-[(1S)-3-[(3-hydroxy-3-methyl-1-oxobutyl)amino]-3-phenylpropyl]-4-piperidinyl]-4-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



IT 498529-71-0P, N-[1-(3-Cyclohexyl-3-Boc-aminopropyl)-4-piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528594-61-8P, N-[1-(3-Phenyl-3-Boc-aminopropyl)-4-piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528596-22-3P, (4'S)-N-[1-(4'-Phenyl-4-Boc-aminobut-2-yl)-4-piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528596-24-5P, N-[1-[3-(2-Thienyl)-3-Boc-aminopropyl]-4-piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide 528596-29-0P, (S)-[3-[4-[Ethyl[2-(4-methanesulfonylphenyl)acetyl]amino]piperidin-1-yl]-1-

[3-fluorophenyl)propyl]carbamic acid tert-butyl ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-piperidinyl benzeneacetamides and their use as modulators of chemokine receptor activity (especially CCR5))

RN 458529-71-0 CAPLUS
CN Carbamic acid, [1-cyclohexyl-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 528586-01-8 CAPLUS
CN Carbamic acid, [3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 528586-22-3 CAPLUS
CN Carbamic acid, [(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylbutyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528586-24-5 CAPLUS
CN Carbamic acid, [3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-(2-thienyl)propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 528586-29-0 CAPLUS
CN Carbamic acid, [(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-(3-fluorophenyl)propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
2002:695949 Document No. 137:232560 Preparation of N-(4-piperidinyl) 4-methanesulfonylphenylacetamides as CCR5 modulators. Burrows, Jeremy; Cumming, John; Tucker, Howard (Astrazeneca AB, Swed.). PCT Int. Appl. WO 2002070479 A1 20020912, 45 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SK, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2002-SE151 20020127. PRIORITY: GB 2001-5077 20010301; GB 2001-15579 20010626; SE 2001-3797 20011113.

GI



AB The title compds. [I; R1 = cycloalkyl, cycloalkyl fused to a Ph ring, cycloalkenyl, heterocyclyl, etc.; R2 = (un)substituted Ph, heteroaryl, cycloalkyl; R2a, R4, R4a = H, alkyl; R3, R3a = H, alkyl, alkoxy; R5 = H, alkyl, haloalkyl, alkenyl, etc.; R6 = Ph, heteroaryl, phenylNH, etc.], useful as modulators of chemokine activity (especially CCR5 activity), were prepared and formulated. Thus, amidation of cyclopentylacetic acid with N-[1-(3-phenyl-3-aminopropyl)-4-piperidinyl]-N-ethyl-4- methanesulfonylphenylacetamide dihydrochloride (preparation given) in the presence of HATU and diisopropylethylamine in NMP afforded II. Certain compds. I had an IC50 of < 50 nM against RANTES or MIP-1α binding in vitro.

IT 458529-28-7P 458529-29-8P 458529-30-1P
458529-31-2P 458529-32-3P 458529-33-4P
458529-34-5P 458529-35-6P 458529-36-7P
458529-37-8P 458529-38-9P 458529-39-0P
458529-40-3P 458529-41-4P 458529-42-5P
458529-43-6P 458529-44-7P 458529-45-8P
458529-46-9P 458529-47-0P 458529-48-1P
458529-49-2P 458529-50-5P 458529-51-6P
458529-52-7P 458529-53-8P 458529-54-9P
458529-55-0P 458529-56-1P 458529-57-2P
458529-58-3P 458529-59-4P 458529-60-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-(4-piperidinyl) 4-methanesulfonylphenylacetamides as CCR5 modulators)

RN 458529-28-7 CAPLUS
CN Benzeneacetamide, N-[1-[3-[(cyclopentylacetyl)amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 458529-29-8 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 458529-30-1 CAPLUS
CN 2-Furancarboxamide, N-[3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]tetrahydro- (9CI) (CA INDEX NAME)



RN 458529-31-2 CAPLUS
CN Benzeneacetamide, N-[1-[3-[(cyclobutylcarbonyl)amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)- (CA INDEX NAME)



RN 458529-32-3 CAPLUS
CN Benzeneacetamide, N-[1-[3-[(cyclohexylcarbonyl)amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)- (CA INDEX NAME)



RN 458529-33-4 CAPLUS
CN Benzeneacetamide, N-[1-[3-[(cyclopentylcarbonyl)amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)- (CA INDEX NAME)



RN 458529-34-5 CAPLUS
CN Benzeneacetamide, N-[1-[3-[(cyclopropylcarbonyl)amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)- (CA INDEX NAME)



RN 458529-35-6 CAPLUS
CN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[3-[(1-oxo-4-pentynyl)amino]-3-phenylpropyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

RN 458529-36-7 CAPLUS
CN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[3-[(1-oxo-4-pentenyl)amino]-3-phenylpropyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)

AB The title compds. [I; R1 = cycloalkyl, cycloalkyl fused to a Ph ring, cycloalkenyl, heterocyclyl, etc.; R2 = (un)substituted Ph, heteroaryl, cycloalkyl; R2a, R4, R4a = H, alkyl; R3, R3a = H, alkyl, alkoxy; R5 = H, alkyl, haloalkyl, alkenyl, etc.; R6 = Ph, heteroaryl, phenylNH, etc.], useful as modulators of chemokine activity (especially CCR5 activity), were prepared and formulated. Thus, amidation of cyclopentylacetic acid with N-[1-(3-phenyl-3-aminopropyl)-4-piperidinyl]-N-ethyl-4- methanesulfonylphenylacetamide dihydrochloride (preparation given) in the presence of HATU and diisopropylethylamine in NMP afforded II. Certain compds. I had an IC50 of < 50 nM against RANTES or MIP-1α binding in vitro.

IT 458529-28-7P 458529-29-8P 458529-30-1P
458529-31-2P 458529-32-3P 458529-33-4P
458529-34-5P 458529-35-6P 458529-36-7P
458529-37-8P 458529-38-9P 458529-39-0P
458529-40-3P 458529-41-4P 458529-42-5P
458529-43-6P 458529-44-7P 458529-45-8P
458529-46-9P 458529-47-0P 458529-48-1P
458529-49-2P 458529-50-5P 458529-51-6P
458529-52-7P 458529-53-8P 458529-54-9P
458529-55-0P 458529-56-1P 458529-57-2P
458529-58-3P 458529-59-4P 458529-60-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-(4-piperidinyl) 4-methanesulfonylphenylacetamides as CCR5 modulators)

RN 458529-28-7 CAPLUS
CN Benzeneacetamide, N-[1-[3-[(cyclopentylacetyl)amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

RN 458529-37-8 CAPLUS
CN Benzeneacetamide, N-[1-[3-[(1,4-dioxopentyl)amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)- (CA INDEX NAME)



RN 458529-38-9 CAPLUS
CN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[3-[[3-(methylthio)-1-oxopropyl]amino]-3-phenylpropyl]-4-piperidinyl]- (CA INDEX NAME)



RN 458529-39-0 CAPLUS
CN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[3-[(1-oxo-5-hexynyl)amino]-3-phenylpropyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 458529-40-3 CAPLUS
CN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[3-[(1-oxo-6-heptynyl)amino]-3-phenylpropyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 458529-41-6 CAPLUS
CN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[3-[(1-oxo-6-heptenyl)amino]-3-phenylpropyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 458529-42-5 CAPLUS
CN Benzeneacetamide, N-[1-[3-[(3-cyclohexen-1-ylcarbonyl)amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)- (CA INDEX NAME)





RN 458529-51-6 CAPLUS
CN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[3-[(1-oxo-3-hexenyl)amino]-3-phenylpropyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 458529-52-7 CAPLUS
CN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[3-[[(methylthio)acetyl]amino]-3-phenylpropyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 458529-53-8 CAPLUS
CN Benzeneacetamide, N-[1-[3-[(cyclobutylcarbonyl)amino]-3-phenylpropyl]-4-piperidinyl]-4-(methylsulfonyl)-N-2-propenyl- (9CI) (CA INDEX NAME)



RN 458529-43-6 CAPLUS
CN Benzeneacetamide, N-ethyl-N-[1-[3-[(2-methyl-1-oxo-2-pentenyl)amino]-3-phenylpropyl]-4-piperidinyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 458529-44-7 CAPLUS
CN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[3-[(1-oxo-2-butynyl)amino]-3-phenylpropyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 458529-45-8 CAPLUS
CN Benzeneacetamide, N-ethyl-N-[1-[3-[(3-methyl-1-oxo-4-pentenyl)amino]-3-phenylpropyl]-4-piperidinyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)

RN 458529-46-9 CAPLUS
CN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[3-[(1-oxo-2-pentenyl)amino]-3-phenylpropyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 458529-54-9 CAPLUS
CN Benzeneacetamide, N-[1-[3-[(cyclobutylcarbonyl)amino]-3-phenylpropyl]-4-piperidinyl]-N-cyclopropyl-4-(methylsulfonyl)- (CA INDEX NAME)

RN 458529-55-0 CAPLUS
CN Bicyclo[4.2.0]octa-1,3,5-triene-7-carboxamide, N-[3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI) (CA INDEX NAME)





RN 458529-47-0 CAPLUS
CN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[3-[(1-oxo-2-butenyl)amino]-3-phenylpropyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 458529-48-1 CAPLUS
CN Benzeneacetamide, N-ethyl-N-[1-[3-[(3-methyl-1-oxo-2-butenyl)amino]-3-phenylpropyl]-4-piperidinyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 458529-49-2 CAPLUS
CN Benzeneacetamide, N-[1-[3-[(2-cyclopenten-1-ylacetyl)amino]-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 458529-50-5 CAPLUS
CN Benzeneacetamide, N-ethyl-4-(methylsulfonyl)-N-[1-[3-[(1-oxo-3-butenyl)amino]-3-phenylpropyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)

RN 458529-56-1 CAPLUS
CN Bicyclo[4.2.0]octa-1,3,5-triene-7-carboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 458529-57-2 CAPLUS
CN 1H-Indene-2-carboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-2,3-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 458529-58-3 CAPLUS
CN 2H-Pyran-4-carboxamide, N-[(1S)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]-1-phenylpropyl]tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 458529-59-4 CAPLUS
CN Bicyclo[4.2.0]octa-1,3,5-triene-7-carboxamide, N-[1-cyclohexyl-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]propyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 458529-60-7 CAPLUS
CN Bicyclo[4.2.0]octa-1,3,5-triene-7-carboxamide, N-[1-(4-chlorophenyl)-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]propyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT 458529-71-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-(4-piperidinyl) 4-methanesulfonylphenylacetamides as CCR5 modulators)
RN 458529-71-0 CAPLUS
CN Carbamic acid, [1-cyclohexyl-3-[4-[ethyl[[4-(methylsulfonyl)phenyl]acetyl]amino]-1-piperidinyl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
2001:851116 Document No. 135:371644 Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity. Burrows, Jeremy; Cooper, Anne; Cumming, John; Mcinally, Thomas; Tucker, Howard (Astrazeneca AB, Swed.). PCT Int. Appl. WO 2001087839 A1 20011122, 122 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-SE1053 20010514. PRIORITY: GB 2000-11838 20000517.
GI



I



II

AB The title compds., e.g., [I; R1 = (un)substituted C1-6 alkyl, C3-7 cycloalkyl, C3-8 alkenyl or C3-8 alkynyl; R2 = H, C1-8 alkyl, C3-8 alkenyl, C3-8 alkynyl, C3-7 cycloalkyl, aryl, heteroaryl, heterocyclyl, aryl (C1-4)alkyl, heteroaryl(C1-4)alkyl, or heterocyclyl(C1-4)alkyl; R3 = C1-8 alkyl, C2-8 alkenyl, mono- or disubstituted amine, C2-8 alkynyl, C3-7 cycloalkyl, C3-7 cycloalkenyl, aryl, heteroaryl, heterocyclyl, aryl (C1-4)alkyl, heteroaryl(C1-4)alkyl, or heterocyclyl(C1-4)alkyl; R4, R5, R6 and R7 = independently H, (un)substituted C1-6 alkyl, (un)substituted S(O)2NH2 or two of R4, R5, R6 and R7 can join to form, together with the ring to which they are attached, a bicyclic ring system or two of R4, R5, R6 and R7 can form an endocyclic bond; X = C(O), S(O)2, C(O)C(O), a direct bond or (un)substituted C(O)C(O)N; m and p = independently 0,1 or 2; or a pharmaceutically acceptable salt or solvate thereof], compns. comprising them, processes for preparing them and their use in modulating CCR5 receptor activity (no data). Thus, reacting isonicotinic acid with 4-methylamino-1-(3,3-diphenylpropyl)piperidine hydrochloride (preparation given) in the presence of diisopropylethylamine in NMP followed by a solution of bromo-tris-pyrrolidinophosphonium hexafluorophosphate in NMP afforded II.
IT 374725-05-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(pharmaceutically active piperidine derivs. as modulators of chemokine receptor activity)
RN 374725-05-0 CAPLUS
CN Benzeneacetamide, N-[1-[3-(benzoylamino)-3-phenylpropyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)- (CA INDEX NAME)



L5 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
2000:456881 Document No. 133:89523 Preparation of acylaminophenylpropylbenzimidazolylazabicycloalkanes and related compounds as CCR5 receptor modulators.. Armour, Duncan Robert; Price, David Anthony; Stammen, Blanda Luzia Christa; Wood, Anthony; Perros, Manoussos; Edwards, Martin Paul (Pfizer Ltd., UK; Pfizer, Inc.). PCT Int. Appl. WO 2000038680 A1 20000706, 205 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1999-IB2048 19991223. PRIORITY: GB 1998-28420 19981223; GB 1999-21375 19990910.
AB RaRbRcRd [Ra = specified (substituted) arylheterocyclyl, amidoaryl, amidoheterocyclyl; Rb = specified (substituted) Et bridging unit; Rc = specified (substituted) azabicyclyl; Rd = specified (substituted) imidazolyl, pyrazolyl, heterocyclyl, amide, carbamate, urea moiety], were prepared as CCR5 receptor modulators (no data). Thus, N-(3-oxo-1-phenylpropyl)cyclobutanecarboxamide (preparation given), exo-1-(8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole (preparation given), and Na(AcO)3BH were stirred 24 h in CH2Cl2/HOAc to give N-[3-[3-exo-(2-methyl- 1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl]cyclobutanecarboxamide dihydrochloride.
IT 280761-45-7P 280761-46-8P 280768-29-8P 280768-30-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of acylaminophenylpropylbenzimidazolylazabicycloalkanes and related compds. as CCR5 receptor modulators)
RN 280761-45-7 CAPLUS
CN Benzeneacetamide, N-[(3-endo)-8-[(3S)-3-[(cyclopropylacetyl)amino]-3-phenylpropyl]-8-azabicyclo[3.2.1]oct-3-yl]-4-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 280761-46-8 CAPLUS
CN Benzeneacetamide, N-[(3-endo)-8-[(3S)-3-[(cyclobutylcarbonyl)amino]-3-phenylpropyl]-8-azabicyclo[3.2.1]oct-3-yl]-4-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 280768-29-8 CAPLUS
CN Benzeneacetamide, N-[(3-exo)-8-[(3S)-3-[(cyclobutylcarbonyl)amino]-3-phenylpropyl]-8-azabicyclo[3.2.1]oct-3-yl]-4-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 280768-30-1 CAPLUS
CN Benzeneacetamide, N-[(3-exo)-8-[(3S)-3-[(cyclopropylacetyl)amino]-3-phenylpropyl]-8-azabicyclo[3.2.1]oct-3-yl]-4-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 280762-44-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of acylaminophenylpropylbenzimidazolylazabicycloalkanes and related compds. as CCR5 receptor modulators)
RN 280762-46-1 CAPLUS
CN Carbamic acid, [(1S)-3-[(3-endo)-3-[[(4-fluorophenyl)acetyl]amino]-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
2000:441322 Document No. 133:58719 Preparation of phenylacetylaminopiperidines and related compounds as CCR5 receptor modulators. Armour, Duncan Robert; Price, David Anthony; Stammen, Blanda Luzia Christa; Wood, Anthony; Perros, Manoussos; Edwards, Martin Paul (Pfizer Inc., USA; Pfizer Limited). Eur. Pat. Appl. EP 1013276 A1 20000628, 90 pp. DESIGNATED STATES: R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO. (English). CODEN: EPXXDW. APPLICATION: EP 1999-309589 19991130. PRIORITY: GB 1998-28420 19981223; GB 1999-22702 19990925.
AB Title compds. RaRbRcRd (Ra = specified arylheterocyclyl; Rb = specified alkyl bridging element; Rc = specified azamonocyclyl moiety; Rd = specified aryl- and heterocyclyl-substituted amide, carbamate, or urea), were prepared as CCR5 modulators (no data). Thus, N-[3-(4-amino-1- piperidinyl)-1-phenylpropyl]cyclobutanecarboxamide (preparation given) was stirred with PhCH2COCl and Et3N in CH2Cl2 to give N-[1-phenyl-3-[4-[(2-phenylacetyl)amino]-1-piperidinyl]propyl]cyclobutanecarboxamide.
IT 277744-99-7P 277745-00-3P 277745-01-4P
277745-02-5P 277745-03-6P 277745-04-7P
277745-05-8P 277745-06-9P 277745-07-0P
277745-08-1P 277745-11-6P 277745-12-7P
277745-13-8P 277745-14-9P 277745-15-0P
277745-16-1P 277745-17-2P 277745-18-3P
277745-19-4P 277745-20-7P 277745-21-8P
277745-22-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenylacetylaminopiperidines and related compds. as CCR5 receptor modulators)
RN 277744-99-7 CAPLUS
CN Benzeneacetamide, N-[1-[3-[(cyclobutylcarbonyl)amino]-3-phenylpropyl]-4-piperidinyl]- (CA INDEX NAME)



RN 277745-00-3 CAPLUS
CN Benzeneacetamide, N-[1-[3-[(cyclobutylcarbonyl)amino]-3-(4-methoxyphenyl)propyl]-4-piperidinyl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 277745-01-4 CAPLUS
CN Benzeneacetamide, N-[1-[3-[(cyclobutylcarbonyl)amino]-3-(3,4-dichlorophenyl)propyl]-4-piperidinyl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 277745-02-5 CAPLUS
CN Benzeneacetamide, N-[1-[3-(3-chlorophenyl)-3-[(cyclobutylcarbonyl)amino]propyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 277745-03-6 CAPLUS
CN Benzeneacetamide, N-[1-[3-[(cyclobutylcarbonyl)amino]-3-(3-fluorophenyl)propyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



CN Benzeneacetamide, N-[1-[(3R)-3-[(cyclobutylcarbonyl)amino]-3-phenylpropyl]-4-piperidinyl]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 277745-14-9 CAPLUS
CN 1-Pyrrolidinecarboxamide, N-[(1S)-1-(3-fluorophenyl)-3-[4-[(phenylacetyl)amino]-1-piperidinyl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 277745-15-0 CAPLUS
CN Benzeneacetamide, N-[1-[(3S)-3-(3-fluorophenyl)-3-[[(1-hydroxycyclopentyl)carbonyl]amino]propyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 277745-16-1 CAPLUS
CN 2H-Pyran-4-carboxamide, N-[(1S)-1-(3-fluorophenyl)-3-[4-[(phenylacetyl)amino]-1-piperidinyl]propyl]tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 277745-04-7 CAPLUS
CN Benzeneacetamide, N-[1-[3-(4-chlorophenyl)-3-[(cyclobutylcarbonyl)amino]propyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 277745-05-8 CAPLUS
CN Benzeneacetamide, N-[1-[3-[(cyclobutylcarbonyl)amino]-3-phenylpropyl]-4-piperidinyl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 277745-06-9 CAPLUS
CN Benzeneacetamide, N-[1-[3-[(cyclobutylcarbonyl)amino]-3-phenylpropyl]-4-piperidinyl]-α-methyl-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 277745-07-0 CAPLUS



RN 277745-17-2 CAPLUS
CN Benzeneacetamide, N-[1-[(2S,3R)-3-[(cyclobutylcarbonyl)amino]-2-methoxy-3-phenylpropyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 277745-18-3 CAPLUS
CN Benzeneacetamide, N-[1-[(3S)-3-[(cyclobutylcarbonyl)amino]-3-phenylpropyl]-4-piperidinyl]-α-methoxy-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 277745-19-4 CAPLUS
CN 2-Pyridineacetamide, N-[1-[(3S)-3-[(cyclobutylcarbonyl)amino]-3-phenylpropyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



CN Benzeneacetamide, N-[1-[3-[(cyclobutylcarbonyl)amino]-3-phenylpropyl]-4-piperidinyl]-α-methyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 277745-08-1 CAPLUS
CN Benzeneacetamide, N-[1-[(3S)-3-[(cyclobutylcarbonyl)amino]-3-phenylpropyl]-4-piperidinyl]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 277745-11-6 CAPLUS
CN Benzeneacetamide, N-[1-[3-[(cyclobutylcarbonyl)amino]-3-phenylpropyl]-4-piperidinyl]-4-methoxy-N-methyl- (9CI) (CA INDEX NAME)



RN 277745-12-7 CAPLUS
CN Benzeneacetamide, N-[1-[3-[(cyclobutylcarbonyl)amino]-3-phenylpropyl]-4-methyl-4-piperidinyl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 277745-13-8 CAPLUS



RN 277745-20-7 CAPLUS
CN 3-Azetidinecarboxamide, 1-acetyl-N-[(1S)-3-[4-[[(4-fluorophenyl)acetyl]amino]-1-piperidinyl]-1-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 277745-21-8 CAPLUS
CN Benzeneacetamide, N-[1-[(3S)-3-[(2,2-dimethyl-1-oxopropyl)amino]-3-phenylpropyl]-4-piperidinyl]-4-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 277745-22-9 CAPLUS
CN Benzeneacetamide, N-[1-[(3S)-3-[(cyclobutylcarbonyl)methylamino]-3-(3-fluorophenyl)propyl]-4-piperidinyl]-4-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 277745-58-1P 277745-59-2P 277745-60-5P
277745-61-6P 277745-62-7P 277745-63-8P
277745-64-9P 277745-65-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)
(preparation of phenylacetylaminopiperidines and related compds. as CCR3 receptor modulators)

RN 277745-58-1 CAPLUS
CN Carbamic acid, [1-(4-methoxyphenyl)-3-[4-[[[4-methoxyphenyl)acetyl]amino]-1-piperidinyl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 277745-59-2 CAPLUS
CN Carbamic acid, [1-(3-chlorophenyl)-3-[4-[(phenylacetyl)amino]-1-piperidinyl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 277745-60-5 CAPLUS
CN Carbamic acid, [1-(3-fluorophenyl)-3-[4-[(phenylacetyl)amino]-1-piperidinyl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 277745-61-6 CAPLUS
CN Carbamic acid, [1-(4-chlorophenyl)-3-[4-[(phenylacetyl)amino]-1-piperidinyl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 277745-62-7 CAPLUS
CN Carbamic acid, [(1S)-1-(3-fluorophenyl)-3-[4-[(phenylacetyl)amino]-1-

PAGE 1-A



PAGE 2-A



L5 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
1997:443325 Document No. 127:65696 Preparation of 3-(4-substituted-piperidino)-1-(3,4-dichlorophenyl)propyl carbamate and urea derivatives as antiasthmatic neurokinin 1 and 2 receptor antagonists. Bernstein, Peter Robert; Dwebsfsky, Bruce Thomas (Fsenece Limited, UK). PCT Int. Appl. WO 9719060 A1 19970529, 67 pp. DESIGNATED STATES: W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, NL, NR, NE, WL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1996-GB2814 19961115. PRIORITY: GB 1995-23526 19951117.
AB The title compds. [e.g., N-benzyl-3-(4-acetamido-4-phenylpiperidino)-1- (3,4-dichlorophenyl)propyl carbamate], a structural definition of which is

presented in the claims, which are nonpeptide antagonists of Substance P (no data) and neurokinin A (no data), and useful for the treatment of asthma (no data), are prepared

IT 191532-33-9P 191532-47-5P 191532-67-9P
191532-78-2P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-(4-substituted-piperidino)-1-(3,4-dichlorophenyl)propyl carbamate and urea derivs. as antiasthmatic neurokinin 1 and 2 receptor antagonists)

RN 191532-33-9 CAPLUS
CN Acetamide, N-[1-[3-(3,4-dichlorophenyl)-3-[[[[(2-methoxyphenyl)methyl]methylamino]carbonyl]amino]propyl]-4-phenyl-4-piperidinyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 191532-47-5 CAPLUS
CN Acetamide, N-[1-[3-(3,4-dichlorophenyl)-3-[[[(2,3-dihydro-1H-inden-1-yl)amino]carbonyl]amino]propyl]-4-phenyl-4-piperidinyl]-, [1(S)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 191532-67-9 CAPLUS
CN Benzenepropanamide, N-[3-[4-(acetylamino)-4-phenyl-1-piperidinyl]-1-(3,4-dichlorophenyl)propyl]-2-methoxy-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

piperidinyl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 277745-63-8 CAPLUS
CN Carbamic acid, [(1S)-1-(3-fluorophenyl]-3-[4-[[(4-fluorophenyl)acetyl]amino]-1-piperidinyl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 277745-64-9 CAPLUS
CN Carbamic acid, [(1R)-3-[4-[[(4-methoxyphenyl)acetyl]amino]-1-piperidinyl]-1-phenylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 277745-65-0 CAPLUS
CN Carbamic acid, [1-(3,4-dichlorophenyl)-3-[4-[[(4-methoxyphenyl)acetyl]amino]-1-piperidinyl]propyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)



RN 191532-78-2 CAPLUS
CN Carbamic acid, [3-[4-(acetylamino)-4-phenyl-1-piperidinyl]-1-(3,4-dichlorophenyl)propyl]-, (2-methoxyphenyl)methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
1995:845995 Document No. 124:86936 Amides of piperidine, morphine and piperazine substituted 1-phenylethylamines: inhibitors of AcylCoA:cholesterol acyltransferase (ACAT) activity in vitro and in vivo. Dugar, Sundeep; Davis, Harry R., Jr.; Burrier, Robert E.; Salisbury, Brian G. (Schering-Plough Research Institute, Kenilworth, NJ, 07033-0539, USA). Bioorganic & Medicinal Chemistry, 3(9), 1231-6 (English) 1995. CODEN: BMECEP. ISSN: 0968-0896. Publisher: Elsevier.

GI



AB Amides of some substituted 1,2-diarylethylamines have been shown to exhibit potent acylCoA:cholesterol acyltransferase (ACAT, EC 2.3.1.26) inhibitory in

vitro in microsomal ACAT assays but show poor in vivo activity in a cholesterol-fed hamster model. In an effort to design ACAT inhibitors that are potent in both our in vitro and in vivo assays a series of amides of piperidine, morpholine and piperazine substituted 1-phenylethylamines were synthesized. Compds. of this series e.g. I (R = oleoyl, Ph2CHCO, etc.; X = CH2, NH, O) were found to be very potent inhibitors of ACAT in a microsomal ACAT assay and also exhibited potent activity in a cholesterol-fed hamster model.

IT 157120-65-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of amides of piperidine, morphine and piperazine substituted 1-phenylethylamines as inhibitors of acylCoA:cholesterol acyltransferase (ACAT))

RN 157120-65-5 CAPLUS
CN 9-Octadecenamide, N-[1-phenyl-2-[4-[(trifluoroacetyl)amino]-1-piperidinyl]ethyl]-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L5 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
1994:533718 Document No. 121:133718 1,2-disubstituted ethyl amides as inhibitors of ACAT. Dugar, Sundeep (Schering Corp., USA). PCT Int. Appl. WO 9406784 A1 19940331, 60 pp. DESIGNATED STATES: W: AU, BB, BG, BR, BY, CA, CZ, FI, HU, JP, KE, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US, VN; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1993-US8705 19930921. PRIORITY: US 1992-950379 19920923.

GI



AB Disubstituted amides I (R1 = cycloalkyl; heterocyclyl, etc.; R2 = Ph, etc.; R3 = alkenyl, long-chain alkenyl, phenylalkyl, etc.; R4, R5, R6 = H, substituent) and pharmaceutically acceptable salts thereof were disclosed. I are useful as inhibitors of acyl-CoA:cholesterol acyl transferase and in the treatment of atherosclerosis. An example compound, (Z)-N-(2-cyclohexyl- 1-phenylethyl)-9-octadecenamide (II). II (10 μM) inhibited ACAT in vitro by 92%.

IT 157120-65-5P
EL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as ACAT inhibitor)

RN 157120-65-5 CAPLUS

CN 9-Octadecenamide, N-[1-phenyl-2-[4-[(trifluoroacetyl)amino]-1-piperidinyl]ethyl]-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



=> FIL STNGUIDE
FILE 'STNGUIDE' ENTERED AT 12:44:36 CM 25 OCT 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Oct 19, 2007 (20071019/UP).

=>
=>